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ABSTRACT

THE ROLE OF O-GlcNAc SIGNALING IN ACUTE MYOCARDIAL
ISCHEMIA
Gladys Afor Ngoh
October 21, 2009
O-linked

~-N-acetylglucosamine

(O-GlcNAc) is an inducible, dynamically cycling,

and reversible post-translational modification of serine/threonine amino acid
residues of nucleocytoplasmic and mitochondrial proteins. O-GlcNAc transferase
(OGT) adds, while O-GlcNAcase (GCA) removes O-GlcNAc from proteins.
Albeit being a recruitable stress-induced signal in other tissues, the role of 0GlcNAc in the heart is unknown. Therefore, we hypothesized that O-GlcNAc is
recruited in the heart during acute stress, and enhanced O-GlcNAc is
cardioprotective. Subjecting neonatal rat cardiac myocytes (NRCMs) to hypoxia,
or mice to myocardial ischemia reduced O-GlcNAc signaling.

Augmented 0-

GlcNAc signaling attenuated, while diminished O-GlcNAc signaling exacerbated
post-hypoxic cardiomyocyte death.

To determine how O-GlcNAc protects, we

identified numerous proteins including voltage dependent anionic channel
(VDAC)

to

be

immunoprecipitation.

O-GlcNAc-modified

via

mass

spectrometry

and

Since VDAC is a putative member of the mitochondrial

VlI

permeability transition pore (mPTP), we hypothesized that one mechanism of 0GlcNAc-mediated cardioprotection

is by blocking mPTP formation.

We

ascertained if O-GlcNAc signaling affects key players in ischemic/hypoxic injury,
Ca 2 + overload and oxidative stress, both inducers of mPTP.

Enhanced 0-

GlcNAc significantly mitigated, while, reduced O-GlcNAc aggravated posthypoxic Ca 2 + overload and ROS generation.

Furthermore, augmented 0-

GlcNAc reduced, while, diminished O-GlcNAc sensitized mitochondria to mPTP
formation according to Ca 2 +-induced swelling.

Since mPTP formation induces

loss of mitochondrial membrane potential (Lll.jJm) , we evaluated whether 0GlcNAc signaling affects post-hypoxic Lll.jJm recovery.

Enhanced O-GlcNAc

significantly improved, while reduced O-GlcNAc minimized post-hypoxic Lll.jJm
recovery.

Because ER stress contributes to ischemia-reperfusion injury, we

evaluated whether inhibiting maladaptive ER stress reponse maybe another
mechanism

through

which

O-GlcNAc

signaling

cardioprotects.

Indeed,

augmented O-GlcNAc reduced maladaptive ER stress response according to
diminished CHOP levels and PI positivity. To determine if such in vitro protection
could be translated in vivo, we augmented O-GlcNAc levels (with PUGNAc) in
adult,

wild-type C57BL6 mice, subjected them to 40 minutes of left anterior

descending coronary artery ligation, then reperfused for 24 hours, and assessed
infarct size.

Augmented O-GlcNAc levels significantly decreased infarct size.

We conclude that O-GlcNAc mediates cardioprotection in vitro and in vivo via
attenuating maladaptive ER stress response and recruitment of early events in
the mitochondrial death pathway leading to mPTP formation.
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CHAPTER I
INTRODUCTION
According to the World Health Organization (WHO), ischemic heart
disease is one of the leading causes of death worldwide, with about 3.8 million
men and 3.4 million women dying yearly from this disease. In the United States,
ischemic heart disease resulting from coronary artery disease is devastating, with
1.5 million US citizens developing myocardial infarctions that account for nearly
200,000 deaths per year (1, 2).

The National Heart Lung and Blood Institute

estimate that an average 14.2 years of life is lost due to a heart attack.
Nine easily measured and potentially modifiable risk factors account for
over 90% of the risk of an initial acute myocardial infarction (MI). The effect of
these risk factors is consistent in men and women, across different geographic
regions, and by ethnic group, making the study applicable worldwide.

These

nine risk factors include cigarette smoking, abnormal blood lipid levels, high
blood pressure, diabetes, abdominal obesity, a lack of physical activity, low daily
fruit and vegetable consumption, alcohol overconsumption, and psychosocial
index (329).

Extensive clinical and statistical studies by the American Heart

Association reveal that in addition to these nine factors, aging, gender, race, and
stress also increase the risk of developing ischemic heart disease.

Despite prevalence of ischemic heart disease, better treatments for
minimizing post-ischemic cardiac injury remain limited.

A primary limitation to

such advances may be our incomplete understanding of why cardiac myocytes
die. Moreover, few ongoing efforts address the metabolic aspect of myocardial
ischemia-reperfusion injury.

The heart is an energy omnivore with energy

requirements exceeding that of any of the body's other organs (274, 275).
Despite its huge energy requirements, the heart has limited energy reserves and
must therefore continually produce large amounts of ATP to sustain its function.
In order to sustain this enormous energy demands, energy metabolism of the
myocardium is coupled to ATP hydrolysis.

It is widely accepted that alterations

in cardiac energy substrate availability have significant effects on the energetic
status of the heart.

Therefore, it is likely that any imbalances to this tightly

regulated system may contribute to the development and, perhaps exacerbate
ischemic heart disease.

Hence, a clear understanding of cardiac metabolism

and its regulation under normal and pathological conditions is essential for the
determination of how any potential treatment could be targeted in an attempt to
alleviate the morbidities associated with ischemic heart disease.
Finally, an ongoing debate is whether the irreversible cardiomyocyte injury
occurs primarily during ischemia or upon reperfusion.

Understanding when

irreversible myocardial injury occurs is relevant, because this would aid in the
development

of

drugs

and

clinically

cardioprotective drugs.

2

allow

the

administration

these

CHAPTER II
BACKGROUND AND LITERATURE REVIEW
1. Acute myocardial infarction (Mil
Commonly known as heart attack, MI is a manifestation of ischemic heart
disease.

It results from decreased or complete blockade of blood flow to the

heart muscle.

The resulting hypoxia decreases both aerobic fatty acid and

glucose oxidation causing damage and potential death of heart tissue. Hypoxia
reduces the oxygen supply to the myocardial cells leading to inhibition of
oxidative

reactions,

diminished

rate

of

ATP

production

by

oxidative

phosphorylation, modulation of protein kinase activities, and changes in the
expression of specific genes (177). Because it is difficult to completely mimic the

in vivo ischemic environment in isolated heart and/or cultured cardiomyocyte
studies, hypoxia combined with procedures that inhibit aerobic glycolysis are
frequently used, so that the main mechanical features of ischemia can be
observed (235).
One hallmark of MI is a reduction in myocardial oxygen supply, i.e. there is
a mismatch between oxygen supply and demand (Figure 1). This is manifested
in a switch of myocardial energy substrate preference from fatty acid to glucose.
Hence, there is a shift in heart metabolism from aerobic fatty acid metabolism to
anaerobic glycolysis, which provides energy for critical myocardial cellular

3

processes (235).

This alteration in substrate utilization results in the uncoupling

between glycolysis and glucose oxidation.

In aerobic glycolysis, glucose is

broken down to pyruvate generating ATP and NADH in glycolysis. This pyruvate
is further converted to acetyl GoA and more reducing molecules are generated in
a process called glucose oxidation. Acetyl GoA then enters Krebs cycle, making
more reducing molecules (NADH and FADH 2 ) through several enzyme catalyzed
reactions.

These reducing equivalents then enter the electron transport chain

where they are utilized to generate electrons to reduce oxygen as well as a
proton motive force necessary for ATP synthesis.

However, in anaerobic

metabolism, glucose oxidation is inhibited and glycolytic pyruvate is no longer
converted to acetyl GoA.

Instead glycolytic pyruvate is reduced to lactic acid

which accumulates in the cytosol causing intracellular acidosis (99).

This

decrease in myocardial intracellular pH alters the sensitivity of contractile
proteins and sarcoplasmic Ga 2 + pump to Ga 2 +.

Decrease in glucose oxidation

also diminishes oxygen-dependent oxidative phosphorylation.

Therefore, the

switch in substrate preference coupled with the change in substrate availability
inhibits mitochondrial oxidative metabolism, forcing the heart to be more
dependent on anaerobic glycolysis for energy its energy requirement (274).
Another consequence of myocardial ischemia is increased glucose
utilization in cardiac tissues (235). The ischemia-mediated increase in glucose
utilization is characterized by enhanced rates of exogenous glucose uptake in

vivo (99, 266) due to increased GLUT 1(26) expression, GLUT 4(281)
translocation to the plasma membrane, and increased hexokinase activity (212).

----------~~-----
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Because glucose transport is an essential metabolic function necessary for cell
survival, alteration in glucose flux through the disruption of blood flow to the
myocardium exerts profound metabolic dysfunction and intricately affects
intracellular physiologic processes. Thus, MI may be considered an acute and
direct metabolic insult.
During reperfusion (or reoxygenation), cardiac myocytes are subjected to
abrupt biochemical and metabolic changes such as mitochondrial reenergization,
generation of reactive oxygen species, intracellular and mitochondrial Ca 2+
overload, restoration of cellular pH and activation of inflammation due to
immediate resumption of oxidative functions as shown in Figure 1(245). During
reoxygenation, damage of sarcolemmal membrane, reverse functioning Na+ Ca 2 + exchanger, and ROS-mediated sarcoplasmic reticulum dysfunction mediate
further Ca 2 + influx into the already Ca 2+-overloaded cardiac myocytes causing
cardiomyocyte

death

via

hypercontracture.

Moreover,

restoration

of

mitochondrial membrane potential drives Ca 2 + entry into the mitochondria. This,
together with the loss of the inhibitory effects of acidic pH on mitochondrial
permeability transition pore (mPTP) and the generation of ROS, mediate mPTP
opening (Figure 1).
dissipating

Opening of mPTP causes cardiac myocyte death by

mitochondrial

membrane

potential,

phosphorylation, and inducing mitochondrial swelling.

- - - - - - - - -•.
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uncoupling

oxidative

Ischemia

Substrate switch from FA to
Glc

Reperfusion

Loss of

membrane

Cell death

Figure 1. Molecular events occurring during myocardial ischemia-reperfusion
injury. During myocardial reperfusion, the ischemic myocardium is subjected to
abrupt biochemical and metabolic changes which adds to the changes generated
during myocardial ischemia. These changes include mitochondrial reenergization
(j.D.ljJm), generation of reactive oxygen species (ROS), intracellular ([Ca 2 +]i) and
mitochondrial ([Ca 2 +]m) calcium overload and the restoration of intracellular pH.
These factors interact with each other and mediate cardiomyocyte death via
mitochondrial permeability transition pore (mPTP) formation. mPTP formation
results in loss of mitochondrial membrane potential (.D.ljJm), massive matrix
swelling, outer mitochondrial membrane rupture, and the release of the apoptotic
signaling protein, cytochrome c, all culminating in cell death.
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1. A. What causes cardiomyocyte death following MI?
1. A. I. Calcium Overload

Ca 2+ primarily enters cardiac myocytes through L-type Ca 2+ channels.
Once in the cell, it induces Ca 2 +-induced-Ca 2 + release from the sarcoplasmic
reticulum (SR).

This increased intracellular calcium leads to cardiac myocyte

contraction during systole.

The Na+-Ca 2 + exchanger (NCX) and sarcolemmal

Ca 2 +-ATPase are responsible for removal of the cytosolic Ca 2 + post contraction
during diastole. NCX removed most of the Ca 2 + that entered the myocyte via Ltype Ca 2 + channels while SR/Endoplasmic Reticulum ATPase (SERCA) removes
the Ca 2 + released by the SR (18, 77).
Ischemia causes intracellular ([Ca 2 +]i) and mitochondrial ([Ca 2 +]m) calcium
overload (Figure 1)(94, 143, 218, 219, 224, 244, 260, 276-278).
source of the rise in [Ca 2 +]j is via reverse functioning NCX.

The primary

Ischemia causes

metabolic acidosis that in turn activates the sodium-hydrogen exchanger (NHE)
which facilitates the extrusion of H+ in exchange for Na + thus, leading to high
intracellular Na + ([Na +]i)(219). Moreover, ischemia induces depolarization of the
plasma membrane.

Both the increased [Na+]i and the depolarization of the

plasma membrane result in the reversal of NCX to bring Ca 2 + into the myocyte.
Studies have shown that interventions that directly (via inhibition of L-type Ca 2 +
channel or NCX) or indirectly (blocking increased [Na+]j via inhibition of NHE)
attenuate the rise in [Ca 2 +]i' and reduce ischemia-reperfusion injury (37, 143,
162, 219, 224, 308).

In the mitochondria, Ca 2 + uptake is via the mitochondrial

Ca 2 + uniporter and it is driven by the mitochondrial membrane potential (~ljJm).
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Hence, [Ca 2 +]m uptake dissipates b.4Jm and unless electron transport continually
resynthesizes this gradient, there will be no driving force for ATP synthesis in the
mitochondria.

Ca 2 + is

removed

from

the

mitochondria

primarily via

the

mitochondrial NCX. The rise in [Ca 2 +]m observed during ischemia is mainly due
to reverse functioning mitochondrial NCX (94).

In fact, blocking mitochondrial

NCX attenuates ischemia-induced [Ca 2 +]m overload (94).
During reperfusion, there is a transient early increase in [Ca 2+]1 as shown
in Figure 1. This is because the slow return of intracellular pH to normal,
facilitates [Na+]j accumulation and subsequently [Ca 2 +]j increase via reverse
functioning NCX.

2

If cardiac myocytes are not permanently damaged, [Ca +]j

returns to near normal levels. But if cardiac myocytes are irreversibly damaged
either due to dysfunction of Ca 2 + handling proteins (262, 271), abnormal [Na+]j
levels (262), or abnormal ATP levels (229), [Ca 2 +]j continues to rise throughout
reperfusion.

Since the

reintroduction

of oxygen during

reperfusion,

and

resumption of oxidative metabolism regenerates b.4Jm, one might expect
significant [Ca 2 +]m uptake.

Indeed, studies have shown an additional rise in

[Ca 2 +]m during reperfusion (94).

1. A. II. Reactive Oxygen Species (ROS) generation
Reactive oxygen species are a class of radical and non-radical oxygencontaining molecules that display high reactivity with lipids, proteins and nucleic
acids. Consequently, ROS are very unstable and highly reactive, and they tend
to initiate chain reactions that result in irreversible chemical changes in lipids or
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proteins. These potentially deleterious reactions can result in profound cellular
dysfunction and even cytotoxicity.

High levels of ROS can trigger cell death,

whereas lower levels drive diverse and important cellular functions. The primary
source of ROS in cardiac myocytes is the mitochondrial electron transport chain
(ETC)(67, 142). Cardiac myocytes are rich in mitochondria, which in addition to
providing the large amount of energy required to maintain cardiac output, can
produce ROS that contribute to ischemia-reperfusion injury (183).

The

mitochondrial ETC produces ROS by the transfer of unpaired electrons from
complex I and from ubisemiquinone of complex III to molecular oxygen (100,
159).

Also, "electron leakage" may contribute to ROS generation.

It is

estimated that approximately 5% of the oxygen consumed by myocytes are
transformed into ROS. Because of this, mitochondria are targets for ROS
damage. Additional sources of ROS generation include neutrophils, oxyradical
generation from xanthine oxidase, autooxidation of catecholamines, activation of
various NAD(P)H oxidases and reactive nitrogen species.

These additional

sources become the primary source of ROS generation when prolonged
ischemia irreversibly disrupts ETC (75, 87).

Basally generated ROS are

efficiently detoxified by endogenous enzymatic antioxidants, such as superoxide
dismutase, glutathione peroxidase, and catalase (211, 314).
conditions

associated with

excess

ROS generation,

However, under

such

as

ischemia-

reperfusion injury, the flux of ROS generated by tissues can exceed the capacity
of endogenous oxidant defense mechanisms to detoxify ROS and prevent
deleterious ROS-mediated reactions.

9

Ischemia/hypoxia augments ROS generation in the intact myocardium and
isolated cardiac myocytes (9, 14, 166). In fact, Zweier et al. demonstrated using
electron spin resonance of frozen ground hearts that 20 minutes of ischemia
increased ROS production (340).
rise in ROS regeneration

Interventions that prevent ischemia-mediated

reduce myocardial ischemia-reperfusion injury.

Indeed, Lesnefsky et al. showed that inhibition of electron transport during
ischemia protects cardiac mitochondria and reduces ischemia-reperfusion injury
(186).
During reperfusion, a large burst of ROS has been consistently shown to
occur (Figure

1)(166, 302, 339). This burst in ROS generation during

reoxygenation has been attributed to damage of electron transport chain
components resulting in inefficient electron transfer. Several studies have shown
that addition of antioxidants or scavengers delay irreversible myocardial damage
or attenuate ischemia-reperfusion injury (7, 43,

168). Overexpression of

manganese superoxide dismutase reduces infarct size in mice (157). Moreover,
treatment of in vivo or in vitro hearts with antioxidants reduced ROS generation
(22).

1. A. III. Mitochondrial permeability transition pore (mPTP) formation
The mPTP is a non-specific pore spanning both the outer mitochondrial
membrane (OMM) and inner mitochondrial membrane (IMM) shown in Figure 2.
This pore allows molecules <1.5kDa to enter and exist the mitochondria. Even
though the molecular composition of mPTP is still debatable, mPTP may reflect
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interaction of several proteins that would connect the mitochondrial matrix to the
cytosolic space.

A relatively simple model was first proposed to constitute

cyclophilin D (CyP-D) in the matrix, adenine nucleotide translocase (ANT) in the
IMM and voltage dependent anionic channel (VDAC) in the OMM (104, 259).
This simplistic model was later made complex by the addition of several other
proteins such as the benzodiazepine receptor (BdR), hexokinase (HK) and
creatine kinase (CK) to accommodate the variety of effectors acting on the mPTP
(205, 259). An alternative model of mPTP proposes that mPTP would be formed
by clusters of misfolded proteins.
mPTP

1

IMM

Figure 2. Mitochondrial permeability transition pore complex (mPTP). mPTP is a
non-specific pore that allows molecules <1.5kDa to pass in and out of the
mitochondria. As described in the text, mPTP is thought to constitute cyclophilin
D (CyP D) in the matrix, adenine nucleotide translocase (ANT) in the inner
mitochondrial membrane (IMM) and voltage dependent anionic channel (VDAC)
in the outer mitochondrial membrane (OMM). Other components thought to
regulate mPTP include benzodiazepine receptor (BdR), Hexokinase (HK) and
creatine kinase (CK). IMS refers to the intermembranous space.
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Voltage dependent anionic channel (VDAC) proteins are the most
abundant protein in the OMM (Figure 2) and exist as three isoforms (VDAC-1,
VDAC-2, and VDAC-3).

VDAC was first discovered over 30 years ago as a

channel protein more permeable to

cr than to K+ (263).

Later, VDAC was shown

to be a single channel with ion selectivity that reacts to membrane potential (51).
Recently, VDAC was shown to transport ATP and interact with molecules that
need to be in close proximity to ATP (258).

VDAC interacts with hexokinase

(206), creatine kinase (265) and members of the Bcl family (BcI-2, Bak and
Bax)(269, 270, 304). Hence, VDAC serves as a binding partner for proteins that
mediate and regulate the integration of mitochondrial functions with other cellular
activities.

VDAC is thought to play a critical role in mitochondrial death

pathways. The role of VDAC in mPTP and mitochondrial-mediated apoptosis is
still being debated.

Earlier reports indicated that VDAC might be required for

cytochrome c release from the mitochondria during apoptosis (269, 270).
Indeed, there is evidence that VDAC-2 plays an important role in suppressing
apoptosis in mice by sequestering Bak and that VDAC-2 null MEFs are more
susceptible to apoptosis (38). Additionally, several lines of evidence suggested
that the OMM protein involved in mPTP formation might be VDAC: purified VDAC
incorporated

into

planar

phospholipid

bilayers

formed

a

channel

with

electrophysiological properties similar to those of mPTP; VDAC channel
properties changed in the presence of NADH, glutamate or Ca 2 +; and finally
chromatography of mitochondrial extracts on a CyP-D matrix allowed for the
purification of VDAC and ANT, which in the presence of CyP-D catalyzed the
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CsA-sensitive permeabilization of liposomes to solutes.

Recently, work by

Krauskopf et al (171) and Baines et al (11) dispute the role of VDAC in mPTP
and apoptosis.

Baines et al. showed that VDACs are dispensable for mPTP

formation (11).

Moreover, eliminating VDAC isoforms by genetic knockout or

knockdown using small interfering RNAs, did not affect mPTP formation.
Furthermore, VDAC-deficient mouse embryonic fibroblast exhibited similar
cellular response and mitochondrial response to Ca 2 + overload, oxidative stress
and Bax-Bid activation as control cells (11).
In

addition

to

their normal

physiological

function

of exchanging

mitochondrial ATP for cytosolic ADP, ANTs has been implicated in cell death.
There exist three ANT isoforms (ANT1, ANT2, and ANT3) in humans and two
isoforms (ANT1 and ANT2) in mice. ANTs operate as gated pores located in the
inner mitochondrial membrane (Figure 2) such that when occupied

by

transportable substrates, they alternate between two conformations in which the
ADP/ATP-binding site is either on the matrix side of the IMM (m-state) or on the
cytoplasmic side (c-state). ANT ligands that bind to the m-state (e.g. bongkrekic
acid,

BKA)

inhibit

carboxyatractyloside

mPTP
(CAT),

formation
pyridoxal

while

phosphate)

c-state
activate

ligands
mPTP.

(e.g.
The

involvement of ANT in mPTP formation was first demonstrated in studies in
which ATP and BKA inhibited opening of the mPTP by decreasing its sensitivity
to Ca 2 + while CAT and adenine nucleotide depletion both triggered pore opening
by sensitizing the pores to Ca 2 +. This notion is now questionable following a
recent study by Kokoszka et al. showing that liver mitochondria from mice lacking
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ANT were sensitive to CsA inhibitable mPTP (169). Moreover, Konkoszka and
Wallace studies revealed that the mPTP in ANT-null mitochondria were
insensitive to opening by atracyloside and to closure by ADP, all compounds that
affect PTP opening through ANT (102, 169).
CyP D, a product of the Ppif gene, is a member of the cyclophilin family.
CyP-D is located in mitochondrial matrix (Figure 2) and exhibits peptidyl-prolyl
cis-trans isomerase (PPlase) activity.

The involvement of CyP-D in mPTP

formation was first suggested when similar concentration of CsA was found to
inhibit mitochondrial cyclophilin activity and block mPTP opening (106, 213).
Moreover, mitochondrial cyclophilin and mPTP showed comparable sensitivities
to CsA analogues (93, 231).

CyP-D favors mPTP opening by facilitating the

Ca 2 +-induced conformational change. Such earlier findings were later confirmed
by studies using CyP-D knockout mice from several groups (10, 12,58, 106,223,
264, 267).

These studies revealed that CyP-D regulates mPTP, CyP-D null

mitochondria were not responsive to Ca 2 +, and CyP-D is a relevant factor for
mPTP modulation but not required for its formation and opening. Additionally,
mPTP formation in CyP-D null mitochondria is not inhibited by the mPTP blocker
cyclosporine A (CsA) and mPTP opening is essential for mitochondrial-mediated
necrotic cell death but dispensable for mitochondrial-mediated apoptotic cell
death (10,12,58,106,223,264,267).
Factors that regulate mPTP can be classified as matrix or membrane
effectors (Table 1). Matrix effectors such as mitochondrial Ca 2 + overload (16,
17), oxidized pyridine nucleotides (40, 61, 63), high inorganic phosphate and
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increased mitochondrial ROS (31, 40, 60, 61, 107) favor PTP, while GsA (24,
64), bongkrekate (140, 180), and matrix pH below 7(16, 17, 104, 141) inhibit
mPTP formation.

Membrane effectors including amphipathic anions (like fatty

acids produced by phospholipase A2 ) favor mPTP (25, 242), while polycations
(spermine)(179), amphipathic cations (sphingosine, trifluoperazine)(25) and
positively charged peptides (253) inhibit mPTP opening.

Table 1: Known inducers and inhibitors of mPTP
Matrix Effectors

Membrane Effectors

Mitochondrial calcium
overload

Favor mPTP

Oxidized pyridine
nucleotides
High inorganic
phosphates
Increased mitochondrial
ROS generation

Amphipathic anions

carboxyatractyloside

Inhibit mPTP

Gyclosporine A (GsA)

Polycations e.g.
Spermine

Bongkrekate

Amphipathic cations e.g.
spingosine

Matrix pH < 7

Positively charged
peptides

Agents that prevent mPTP formation attenuate ischemia-reperfusion
injury. In fact, known mPTP inhibitors, cyclosporine A (GsA) and it analog
sanglifehrin A,

have been shown to protect cardiac myocytes against

reoxygenation injury (95, 227, 320) and decrease infarct size in various species
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(122, 123) . CsA has also recently been shown to reduce infarct size in humans
during percutaneous coronary intervention procedure (243).
cardioprotective

interventions

such

as

ischemic

Furthermore,

preconditioning,

ROS

scavengers, inhibitors of the Na +-H+ exchanger and Ca 2 + antagonists have been
shown to inhibit mPTP formation as part of the mechanisms through which they
confer cytoprotection (68, 101, 104). In addition, mice lacking CyP-D, a putative
mPTP component are less susceptible to ischemia-reperfusion injury (10, 223).
The inhibitory effect of CsA and its analogs involves interaction with CyP-D that
reduces sensitivity of pore opening to Ca2 +.

1. A. IV. Endoplasmic Reticulum (ER) stress

Proper protein synthesis, folding, and transport are essential for cell
survival.

The rough endoplasmic reticulum (ER) is involved with maintaining

proper synthesis, folding, and transport of proteins targeted to membranes and
organelles (20). Conditions that alter the ionic balance, molecular chaperones,
protein glycosylation machinery, and/or redox status of the ER lumen cause ER
stress and trigger an intracellular signaling system called the unfolded protein
response (UPR, Figure 3)(23, 36, 163, 195, 261).
adaptation to reestablish normal ER function.

Initially, the UPR promotes
Such adaptation occurs by

reducing the quantity of protein synthesized in the ER, inducing the expression of
genes that enhance protein folding capacity of the ER, promoting ER-associated
protein degradation to remove misfolded proteins, and reestablishing the ER
luminal environment to that suitable for new protein synthesis and folding (Figure
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3).

Such initial responses are designed to resolve the stress and ultimately

enhance the chances of survival, but if the ER stress is prolonged, the
maladaptive arm of the UPR is activated causing cell death as shown Figure 3
(284).
ER stress has been implicated in the pathogenesis of several diseases
including ischemia-reperfusion injury (249, 293).

One study showed that

numerous UPR genes are induced within 24 hours of myocardial infarction in
mice (117). Moreover, several studies have shown that interventions that inhibit
ER stress in the heart attenuate ischemia-reperfusion injury in mice or hypoxic
injury in cultured cardiac myocytes (230, 249, 286, 289).
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Figure 3. Unfolded protein response (UPR). Under non-stressed conditions,
proteins synthesized in the ER are efficiently folded. Stressors that perturb the
ER protein glycosylation machinery, ER Ca 2 + levels, and/or redox status results
in accumulation of misfolded proteins in the ER and initiates the unfolded protein
response (UPR). The initial action of the UPR is geared towards restoring normal
ER environment via increased synthesis of ER chaperones (e.g. glucose
regulated peptides 94(Grp 94) and 78 (Grp 78)), calcium binding proteins
(e.g.calreticulin) and protein disulfide isomerases (PDI)). If ER stress is not
resolved during the prosurvival phase, maladaptive UPR is activated leading to
apoptosis. CHOP/GADD153 - growth arrest and DNA damage 153.
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1. B. Cardioprotective mechanisms
1. B. I. Ischemic Preconditioning

Inducing brief non-lethal episodes of ischemia and reperfusion to the heart
prior to an episode of sustained lethal myocardial ischemia has the capacity to
dramatically reduce myocardial ischemia-reperfusion injury. This phenomenon,
termed ischemic preconditioning (I PC), is a transient, self-defense mechanism
present in the heart and many other organs including the kidney, liver, and brain
(220).

IPC significant and reproducible and serves as the gold standard for

studies of cardioprotection (152). IPC reduces myocardial infarct size, lactate
generation and rate of fall of ATP.

There are two "windows" of protection

afforded by preconditioning, "early" and "late" preconditioning. The protective
effect of early IPC is mediated by posttranslational modification and is lost if the
time between the initial IPC protocol and the sustained ischemia is greater than
one hour (292). The late or second window of preconditioning involves gene up
regulation and occurs 24 hours after preconditioning.
Intense investigation of the mechanisms responsible for the protective
effects of preconditioning has revealed numerous potential mediators and
downstream effectors of preconditioning (Figure 4), but cause and effect
relationships have not been fully delineated. However, Tong et al. and others
have successfully demonstrated that ischemic preconditioning enhances glucose
uptake (147, 296, 309). Moreover, preconditioned hearts have less anaerobic
glycolysis, hence make less lactate and have less acidic pH during ischemia
(221, 278). Interestingly, the rate of ATP consumption is slower for PC hearts

19

(221, 278). Two hypotheses have been put forward to explain why PC hearts
have reduced ATP hydrolysis: 1. IPC might inhibit ATP breakdown by reverse
mode functioning of mitochondrial ATP synthase confirmed by in vitro and in vivo
data from several groups (69, 97, 149, 187,207,328). 2. The ATPase inhibitor
subunit might bind to and inhibit the mitochondrial ATPase during IPC.

Data

from several groups show that IPC and diazoxide enhance early binding of
ATPase inhibitor subunit to mitochondrial ATPase (6, 52, 59). Contrarily,
Grover's (89) and Jennings' (303) groups found no evidence supporting inhibition
of ATP synthase in PC hearts. IPC has also been shown to decrease Ca 2 +
overload (218), oxidative stress (301), and PTP formation (123, 148).
Recent studies suggest that IPC also activates several signaling pathways
(Figure 4). The most prominent is the activation of G-protein coupled receptors.
Activation of GPCRs leads to activation of the phosphoinositide-3-kinase (PI3K)
pathway.

The

action

of

PI3K

is

attributed

phosphatidylinositol 3,4,5-phosphate (PIP3).

to

the

generation

of

PIP 3 facilitates phosphoinositide-

dependent protein kinase 1 (PDK1) phoshorylation and activation of substrates
like Akt (PKB), p70S6K, Protein Kinase C (PKC), extracellular regulated kinase
(ERK), p38 MAPK, JNK, PKC-E, and eNOS/NO to mediate cardioprotection. In
fact, Tong et a/ showed PC induced Pl3K-mediated cardioprotection was via
activation of targets upstream of PKC (297). Moreover, phosphatase and tensin
homolog deleted chromosome ten (PTEN) which regulates PIP 3, is degraded
during PC and might be involved in GPCR recycling (30, 73, 298).
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proteosome

IPC

~

[-m""';'PT-p-)
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Ischemic preconditioning
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Figure 4. Summary of signaling pathways activated by ischemic preconditioning
and postconditioning. IPC leads to release of agonists that activate G proteins
coupled receptor (GPCR), leading to activation of phosphoinositide 3-kinase
which in turn activates protein kinase B (PKB or AKT), PKA, PKC, and
extracellular regulated kinase (ERK) signaling pathways. These pathways
converge on the mitochondrial where they inhibit mitochondrial permeability
transition pore (mPTP) formation. PIP2 - phosphatidylinositol 3,4-diphoshpate,
PIP3 - phosphatifylinositoI3,4,5-triphoshate, PDK1 - protein dependent kinase
1, PTEN - phosphatase and tensin homolog deleted on chromosome ten, GSKglycogen synthase kinase, eNOS - endothelial nitric oxide synthase.
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1. B. II. Reperfusion Injury Survival Kinases (RISK pathway)
The RISK pathway refers to a group of protein kinases that when activated
during myocardial reperfusion confers cardioprotection (126, 327).

Extensive

preclinical data have amassed showing that pharmacologic preconditioning (126,
127), IPC, or postconditioning(124) activation of RISK pathway reduces infarct
size by up to 50%.

Indeed, Hausenloy et al. showed that ERK and Akt were

activated at the start of reperfusion and blockade of ERK and Akt at the start of
reperfusion blocks PC-mediated protection in PC hearts (124). RISK pathway is
thought to reduce myocardial ischemia-reperfusion injury by inhibiting mPTP
formation(66), improving SR calcium uptake (3, 246) and by activation of
antiapoptotic pathways (327).

1. B. III. Postconditioning
Interrupting myocardial reperfusion with brief cycles of myocardial
ischemia and reperfusion reduces infarct size.

This phenomenon, termed

ischemic postconditioning, was first reported by Zhao et al in 2003 (335). In this
study, after 45 minutes of sustained myocardial ischemia in dogs, the interruption
of reperfusion with three 30 second cycles of ischemia and reperfusion reduced
myocardial infarct size from 47% to 11 % (335). Thus, the myocardial reperfusion
phase could be a target of cardioprotection. Although the exact mechanisms
through which postconditioning confers protection are not fully understood,
postconditioning has been shown to inhibit lethal reperfusion injury through the
same mechanisms as IPC (Figure 4)(124). Postconditioning activates PI3K
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pathway which results in the activation of downstream targets like PKC,
PKG/NO, and MAPK to mediate cardioprotection. Ischemic postsconditioning
also targets important mediators of ischemia-reperfusion injury such as oxidative
stress, [Ca 2+]j overload, neutrophil accumulation (336) and cellular pH (49).
Moreover, ischemic postconditioning activates the RISK pathway (126) and
blocks opening of the mPTP (125).

2. Hexosamine Biosynthetic Pathway (HBP)
Intracellular glucose normally provides substrate for metabolic processes.
In general, upon entering the cell, glucose is rapidly phosphorylated by
hexokinase to glucose-6-phosphate which either enters glycogen metabolism or
reversibly converted to fructose-6-phosphate for primarily glycolysis (Figure 5).
Thus, glycogen synthesis and glycolysis uses ==90-95% of cellular glucose. Less
than 5% of the remaining cellular glucose is shunted to a unique accessory
pathway, the hexosamine biosynthetic pathway (208). This pathway involves a
series of enzyme catalyzed reactions ending with the formation of uridine
diphosphate-N-acetylglucosamine (UDP-GlcNAc, Figure 5). HBP begins with the
rate limiting conversion of fructose-6-phosphate to glucosamine-6-phosphate by
L-glutamine: fructose-6-phosphate amidotransferase (GFAT) using glutamine as
the amide donor (Figure 5). The next critical reaction involves the modification of
the hexosamine core in the conversion of glucosamine-6-phosphate to Nacetylglucosmaine-6-phosphate by glucosamine-6-phosphate acetyltranseferase
(Emeg32) using acetyl-coenzyme A (CoA, Figure 5). The final step involves
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exergonic

pyrophosphorylation

of

diphosphate-p-N-acetylglucosamine
pyrophosphorylase (Figure 5).

glucosamine-1-phosphate
(UDP-GlcNAc)

by

to

uridine

UDP-GlcNAc

Once formed, UDP-GlcNAc serves as the

glycosidic precursor for glycoproteins, glycolipids, proteoglycans, and more
germane to this research project, serves as the nucleotide sugar for the posttranslational glycosylation of nuclear, cytoplasmic and mitochondrial proteins (0GlcNAc).

Despite using less than 5% of cellular glucose, UDP-GlcNAc, is

second only to ATP in terms of the intracellular concentration of high energy
compounds (209).

Flux through HBP can be increased by adding exogenous

glucosamine. Glucosamine enters the cell via a glucose transporter and is
phosphorylated by hexokinase to glucosamine-6-phosphate, thus by-passing
GFAT and rapidly increasing UDP-GlcNAc levels(204).
Data on how the critical enzymes of the HBP are regulated is
unexpectedly very limited. GFAT activity is glutamine-dependent and can be
inhibited by the glutamine analogues 6-azido-5-oxo-L-norleucine (DON) and 0diazoacetyl-L-serine (azaserine)(215). There are two isoforms of GFAT; GFAT1
and GFAT2 transcribed from separate genes. GFAT1 is highly expressed in the
pancreas, placenta and testes while, GFAT2 is more abundant in the heart and
central nervous system. Eukaryotic GFAT is highly conserved and regulated
transcriptionally

(241),

post-translationally

by

cAMP-dependent

protein

kinase(35, 136) and by UDP-GlcNAc feedback inhibition (88). Phosphorylation
of GFAT1 decreases its activity while phosphorylation of GFAT2 increases its
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activity.

Emeg32, another critical enzyme of the HBP, is important for

maintaining proper intracellular UDP-GlcNAc concentration (21).
The diverse nature of the precursors of UDP-GlcNAc potentially links HBP
to several metabolic pathways (Figure 5).

First, less than 5% cellular glucose

siphoned to the HBP (203). Second, glutamine, a nonessential amino acid highly
abundant in muscle cells enters the HBP at the rate limiting step, potentially
linking HBP to amino acid metabolism. Third, acetyl-CoA, produced primarily
from fatty acid and pyruvate oxidation in the mitochondria, enters HBP during the
acetylation of the glucosamine core to form N-acetylglucosamine-6-phosphate,
possibly links HBP to fatty acid metabolism. Finally, ATP enters the HBP at the
final step i.e. the conversion of N-acetylglucosamine-1-phosphate to UDPGlcNAc

by

UDP-GlcNAc

pyrophosphorylase,

linking

HBP

to

nucleotide

metabolism. Therefore, UDP-GlcNAc and hence O-GlcNAc might act as a
nutrient and/or metabolic sensor.
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Figure 5. Hexosamine biosynthetic pathway (HBP) . Once cells take up glucose,
it is first phosphorylated by hexokinase. This phosphorylated glucose either
enters glycogen synthetic pathway or is further converted to fructose-6phosphate by glucose-6-phosphate isomerase. The majority of fructose-6phosphate is channeled to glycolysis. Of the remainder, between <5% is
channeled to an accessory pathway for glucose metabolism, the hexosamine
This pathway begins with the rate limiting
biosynthetic pathway (HBP).
conversion of fructose-6-phosphate to glucosamine-6-phosphate by Lglutamine:D-fructose-6-phosphate amidotransferase (GFAT). The next critical
reaction involves acetylation of gluocsamine-6-Phosphate by glucosamine-6phosphate acetyltransferase (Emeg32) to for N-acetylglucosamine-6-phosphate
(GlcNAc-6-P). Next are two reversible reactions: first the conversion of GlcNAc6-P to GlcNAc-1-P by phosphate-acetylglucosamine mutase, and then the
formation uridine diphosphate- GlcNAc (UDP-GlcNAc) by UDP-GlcNAc
pyrophosphorylase.
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3. What is O-GlcNAc

3. A. O-GlcNAc biology
Beta-O-linked N-acetylglucosamine (O-GlcNAc) is a post-translational
sugar modification of eukaryotic proteins (Figure 6) first described in 1984 by
Torres and Hart in a study in which soluble

~-1-4

galactosyltransferase was used

to probe lymphocyte plasma membrane for surface glycans (300). This study
was ground breaking at that time because not only were glycosylated proteins
thought to exist only in luminal compartments and on cell surfaces, but, also all
glycosylation processes were thought to be largely static. The addition of 0GlcNAc to proteins from UDP-GlcNAc stores is a metabolic post-translational
modification occurring in the cytoplasm, nucleus, and potentially mitochondria.

OH

OH

HO-,:--~

o
AcNH

t

___
o

I
OGT, GCA

AcNH

ft

Tyr-Ser-Pro-Thr-Ser-Pro-Thr

Figure 6. O-GlcNAc transferase (OGT) adds, while O-GlcNAcase (GCA)
removes GlcNAc molecule from Ser/Thr residues of mature nuclear, cytoplasmic
and mitochondrial proteins.
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O-GlcNAcylation is in many ways distinct from the "classical" protein
glycosylation in that: 1. O-GlcNAc modified proteins are found mostly within the
nucleus, cytoplasm or mitochondria versus cell surfaces, the lumen of
membranous organelles, the endoplasmic reticulum and Golgi apparatus for Nglycosylation (118, 138). 2. O-GlcNAc is not elongated into complex structures
or further modified (with the exception of nuclear pore protein) unlike the
extraordinarily complex array of glycans found on extracellular glycoproteins
(131, 132, 300). 3. O-GlcNAc rapidly cycles on and off proteins on a time scale
similar to that for phosphorylation/dephosphorylation,

unlike extracellular

complex glycans, which are static (70, 79, 176, 255). 4. There is no obvious
consensus sequence for the addition of O-GlcNAc to proteins while Nglycosylation has Asn-X-Ser/Thr sequence (where X could be any amino acid
other than proline or aspartic acid). 5. GlcNAc is added to proteins through an 0linkage on the hydroxyl group of Ser/Thr while in N-glycosylation the
monosaccharide is added through an N-linkage on the amide group of Asn.
Akin to phosphorylation, O-GlcNAcylation is one of the most common
post-translational modifications. O-GlcNAc is similar to a protein phosphorylation
in

that:

1.

Both

O-GlcNAcylation

and

phosphorylation

post-translational

modifications are found on serine and threonine residues (119, 120). 2. Both
modifications are dynamically added and removed from proteins in response to
cellular signals (44, 45, 160). 3. Both alter the functions and associations of the
modified protein. Conversely, O-GlcNAc differs from protein phosphorylation in
that only two enzymes control the addition and removal of the O-GlcNAc post-
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translational modification from proteins, while over 600 genetically distinct
kinases and phosphatases exist in mammalian cells.
O-GlcNAc modified proteins do not have a consensus sequence, but most
of the sites of O-GlcNAc addition mapped so far have a Pro-Val-Ser motif similar
to that recognized by proline-directed kinases. Moreover, many phosphorylation
sites are also known glycosylation sites (44, 45). O-GlcNAc and O-phosphate
site-mapping studies so far suggest that there are at least four different types of
dynamic interplay between O-GlcNAc and O-phosphate. There is evidence of
competitive occupancy at the same site; for example, that which occurs in the
transcription factor c-Myc(46, 47, 160), estrogen receptor-j3(39), oncoprotein SV40 large T-antigen(214) and endothelial nitric oxide synthase(74). In competitive
occupancy, O-GlcNAcylation and O-phosphorylation compete for the same site
and have antagonistic effects.

Next, there exist competitive and alternative

occupancy occurring at adjacent sites, such as in tumor suppressor p53(323)
and synapsin 1(50).

Hence, it is possible that O-GlcNAcylation can inhibit

phosphorylation at adjacent sites by steric hindrance or modulation of protein
structure. Another, interplay between O-GlcNAc and O-phosphate described is a
complex interplay whereby some O-phosphate attachment sites on a given
protein are the same as some O-GlcNAc sites, whereas others are adjacent to,
or even distant from each other, as on the C-terminal domain of RNA polymerase
11(53) and on cytokeratins 8 and 18(45). The finally type of interplay involves
proteins in which this relationship has yet to be clearly defined. The interplay
between O-GlcNAc and O-phosphate is also underscored by the recent finding

29

that OGT transiently forms complexes containing the catalytic subunit of protein
phosphatase 1 (PP1 c)(311), hence there may exist a single enzyme complex for
the addition of GlcNAc and removal of phosphate. Additionally, many known 0GlcNAc sites have the PEST sequence (Pro-Glu-Ser-Thr), a sequence
associated with rapid degradation suggesting that O-GlcNAcylation at these sites
might slow or prevent protein degradation(113). O-GlcNAcylation affects protein
trafficking and localization for example c-Myc (160), Tau(182), and Stat5a(85,
225) have a larger portion of the O-GlcNAcylated form located in the nucleus
than cytoplasm.

3. B. Enzymatic regulation of O-GlcNAc cycling

Modulation of protein O-GlcNAcylation is achieved by the concerted action
of two highly evolutionarily conserved enzymes, a uridine diphospho-Nacetylglucosamine: peptide J3-N-acetylglucosaminyl transferase (OGT) and

0-J3-

N-acetylglucosaminidase (O-GlcNAcase aka GCA, OGA, or MGEA5).
O-GlcNAc transferase (OGT) is a soluble, ubiquitously expressed, and
highly conserved enzyme in all multicellular eukaryotic organisms involved with
the addition of a single J3-N-acetylglucosamine (GlcNAc) moiety (from UDPGlcNAc) via an O-linkage to serine/theronine amino residues of mature nuclear,
cytoplasmic and mitochondrial proteins as shown in Figure 6( 110, 112, 173,
199). OGT is expressed in all examined tissue types and is most abundant in the
glucose-sensing cells of the pancreas and in the brain. OGT is primarily located
in the nucleus and has an optimum pH of about 6(173, 199). OGT is encoded by
a single copy X-linked gene in mammals while plants have two OGT homologs
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spy and secret agents (121, 173, 199, 268). Even though OGT is coded by a
single gene in mammals, alternative splicing of OGT mRNA leads to three
potential

isoforms,

nucleocytoplasmic OGT (ncOGT),

mitochondrial

OGT

(mOGT) and short OGT (sOGT)(173, 199, 232). These isoforms share an
identical C-terminal catalytic domain but have distinct N-terminal domains
contributing to their differential localization and unique targeting sequences (115,
198, 232). Structurally, OGT contains an N-terminal tetratricopeptide repeat
(TPR), a linker region and C-terminal catalytic domains (173,199). TPR domain
consists of a 34 amino acid repeat varying from 3-12 involved in inter-subunit
interaction,

protein-protein

interaction,

subcellular

targeting,

substrate

recognition, cell cycle regulation and transcriptional control (13, 144, 145, 151,
174, 199, 326). The linker region is the least conserved sequence of OGT. The
catalytic domain of OGT is thought to have a UDP-GlcNAc binding site and is
involved with the glycosylation of proteins (319). Post-translational modification
of OGT by tyrosine phosphorylation and O-GlcNAc modification, UDP-GlcNAc
concentration and protein-protein interaction are thought to regulate OGT activity
(42, 173, 199). Recently, insulin signaling was shown to regulate OGT (316,
324). In these studies, insulin increased post-translational OGT phosphorylation
and O-GlcNAcylation, OGT activity and transient translocation from nucleus to
the cytoplasm (316, 324). In neuro-2a neuroblastoma cells, OGT mRNA and
protein expression are regulated in an AMP-activated protein kinase-dependent
manner, whereas OGT enzymatic activity is regulated in a p38 MAPK-dependent
manner (41). Moreover, activated p38 has been shown to interact with OGT and
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recruit it to specific substrates, such as neurofilament H during glucose
deprivation in neuroblastoma cells (41). Tissue specific OGT mutation causes
disturbance in somatic cell function(234) while OGT deletion is embryonically
lethal(268), hence O-GlcNAc is important for cellular viability.
O-~-N-acetylglucosaminidase

(O-GlcNAcase, aka GCA, OGA, or MGEA5)

is a soluble, highly conserved enzyme, expressed in all eukaryotic organisms
involved with the removal of O-GlcNAc modification from proteins (Figure 6)(84).
O-GlcNAcase is primary located in the cytoplasm with an optimum pH of 5.5-7
and coded for by a single gene. Structurally, O-GlcNAcase is a 917 amino acid
protein

with

an

N-terminal

hexosaminidase

and

a

C-terminal

histone

acetyltransferase domain (HAT)(56, 78, 84, 130, 295). The N-terminal domain is
similar to hyaluronidase and was originally identified as a meningioma expressed
antigen 5(56, 78, 84, 130). While there may be some activity against hyaluronan,
the preferred substrate for O-GlcNAcase is O-GlcNAc (84, 310). The C-terminal
histone acetyltransferase domain acetylates free histones and nucleosomal
histone proteins (295).

O-GlcNAcase is cleaved by caspase 3 into HAT and

hexosaminidase domains with no change in the activity of each domain. Proteinprotein interaction and phosphorylation are thought to regulate O-GlcNAcase
activity (84, 310). Two splice variants of O-GlcNAcase have been reported in
rats, both lacked O-GlcNAcase activity but retained HAT activity. The spliced
variant detected in Goto-Kakizaki rats (-90kDa) lacks exon 8 while the spliced
variant in Sprague-Dawley (-84kDa) lacks both exons 8 and 9.
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The fact that OGT is known to associate with histone deacetylase
complexes(326) and promote transcriptional silencing (326), while O-GlcNAcase
has a HAT domain(295), has led to the hypothesis that O-GlcNAcylation plays a
role in the regulation of transcription. Such hypothesis has been supported by
studies identifying numerous transcription factors to be regulated by O-GlcNAcmodification (146, 165, 178, 325).

O-GlcNAcylation can either suppress or

enhance transcription, depending on the promoter involved and other associated
proteins. The transcription factor STAT5A is known to alter gene activation by
preferentially binding to the co-activator of transcription, CREB-binding protein
when O-GlcNAc modified (85). O-GlcNAc modification of Sp1 has multiple effects
on the function of the transcription factor (146).

Augmented O-GlcNAc

modification of SP1 has been shown to drive the transcription of plasminogen
activator and extracellular matrix proteins that have an important role in diabetic
cardiovascular disease while reduction of Sp1 glycosylation led to an increase in
Sp1 proteasome susceptibility (113).

3. C. Pharmacologic regulation of O-GlcNAc cycling
Pharmacological approaches to beUer understand the role of enzymes
controlling the presence of O-GlcNAc on proteins in biological and pathological
processes have been limited due to lack of specific high-affinity inhibitors (Table
2). Alloxan, a uracil and UDP-GlcNAc analog, may be an irreversible inhibitor of
OGT (170). The drawbacks of this compound include its ability to inhibit many
other enzymes using uridine as substrate, its reactivity with many cellular
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components like DNA (285) and also, its ability to inhibit O-GlcNAcase(181}.
Compounds "4" (aka TT04) and "5" (aka TT40) inhibit OGT by competing with
UDP-GlcNAc for the same site on OGT(96}; however, there are relatively few
reports of their use in biological systems.

O-GlcNAcase, unlike OGT, has

several known pharmacologic inhibitors. Streptozotocin (STZ), a diabetogenic
compound and GlcNAc analog, inhibits O-GlcNAcase by binding to its active site,
leading to the formation of energetically more stable transition state ligands (254,
294).

Results from studies using STZ as an O-GlcNAcase inhibitor should be

interpreted with caution because of its cytotoxic effects on pancreatic cells and its
ability to reduce cellular NAD levels (27). Whether the STZ-mediated increase in
O-GlcNAc levels is due to secondary or other toxic effects remains debatable.
Furthermore, Macualey et al. showed that STZ had no effect on O-GlcNAcase
activity in vitro (200). PUGNAc, a GlcNAc analog, prevents the binding of 0GlcNAcase to GlcNAc (134). Even though PUGNAc lacks the cytotoxic effects of
STZ(111}, it inhibits other lysosomal hydrolases and shows little specificity for 0GlcNAcase

over

hexosaminidase

(200).

1,2-dideoxy-2-methyl-D-

glucopyranoso[2,1-d]-2-thiazoline (NAG-thiazoline) and its derivatives inhibit 0GlcNAcase and have 1500-fold greater specificity for O-GlcNAcase over
hexosaminidase than PUGNAc(200}. GlcNAcstatin, a glucoimidazole-based
inhibitor, has been shown to inhibit O-GlcNAcase in the picomolar range with
100,OOO-fold selectivity over lysosomal hexosaminidase in human embryonic
kidney 293 and SH-SY5Y neuroblastoma cell lines but has not been as widely
studied as PUGNAc (71). This may be more selective and potent than PUGNAc
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and NAG-thiazoline. Thiamet-G, another O-GlcNAcase inhibitor, has also
recently been developed (330). Again, few studies have addressed the role of 0GlcNAcase inhibition beyond the use of PUGNAc or NButGT. As with inhibitors
of OGT, concern remains regarding the off-target effects of PUGNAc, ST2, and
other putative inhibitors of O-GlcNAcase. Thus, the use of other approaches,
such as RNA interference or adenoviruses, could clarify some of the off-target
effects of the aforementioned pharmacologic approaches.

Table 2: Common pharmacologic inhibitors of OGT and GCA
O-GlcNAc Transferase (OGT)

O-GlcNACase (GCA)

Alloxan (Konrad et aI., 2002)

PUGNAc (Horsch et aI., 1991)

Compound 4 (Gross et aI., 2005)

Streptozotocin (Roos et aI., 1998)

Compound 5 (Gross et aI., 2005)

Alloxan (Lee et aI., 2006)
NButGT (Macauley et aI., 2005)
GlcNAcstatin (Dorfmueller et aI., 2006)
Thiamet-G (Yuzwa et aI., 2008)

3. D. Detection tools and methods
Despite its abundance and discovery two decades ago, few protein targets
have been unequivocally and site-specifically identified as carrying an O-GlcNAc
modification. This is due to the lack of specific and sensitive methods, which are
further limited by the relatively labile nature of the modification, its limited mass,
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its fast turnover(45, 255) and its lack of charge(315).

One of the earlier

developed approaches relied upon enzymatic labeling of terminal O-GlcNAc
residues with radioactive uridine diphospho-galactose (UDp[3H]Gal) using
galactosyltransferase (114, 133, 256, 299).

Since O-linkage of GlcNAc to

protein is resistant to peptide/N-glycosidase F (PNGase F), nonspecifically
UDp[3H]Gal tagged N-linked oligosaccharides were cleaved by PNGase F
treatment. The main limitation of this technique was that O-GlcNAc is not readily
accessible to galactosyltransferase. Hence, galactosyltransferase will recognize
any terminal

GlcNAc residue,

oligosaccharides.

such

Consequently,

as those found

definitive

in many N-linked

identification

modification requires further carbohydrate characterization.

of

O-GlcNAc

In addition, the

donor sugar UDP-[3H]galactose has a very low specific activity (17-20 Cilmmol),
making this method insensitive compared to radiolabeling techniques with other
isotopes, such as [32P]phosphate, with specific activities as high as 6000
Ci/mmol.

Such a low specific activity of the sugar donor may require several

weeks of exposure to detect O-GlcNAc.
Plant lectins like wheat germ agglutinin (WGA) or succinylated WGA have
also been used for the detection and purification of O-GlcNAc-containing proteins
(41, 288, 321). WGA does not recognize GlcNAc in a linkage-specific manner
and therefore, samples must first be treated with peptide: N-glycosidase F
(PNGase F) to remove the N-linked sugars.

Another disadvantage of this

method is that sWGA is less sensitive and only proteins with multiple O-GlcNAc
residues are readily detected. Sensitivity may be improved by using sWGA-
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conjugated sepharose column to isolate and enrich O-GlcNAc-modified proteins
from cell extracts. Thus, the identification of O-GlcNAc by this existing method
requires further carbohydrate analysis for confirmation.
Several monoclonal antibodies that recognize O-GlcNAc are commercially
available, the most commonly used of these antibodies are referred to as
RL2(133, 239, 272) and CTD110.6(S4).

RL2, generated against nuclear pore

glycoproteins, recognizes a limited subset of O-GlcNAc proteins and requires
protein determinants in addition to O-GlcNAc. CTD110.6, a murine monoclonal
IgM raised against the O-GlcNAc-modified C-terminal domain of the RNA
polymerase II large subunit, specifically recognizes single O-GlcNAc residues in
~-O-glycosidic

linkage to serine and threonine.

CTD110.6 shows no apparent

cross-reactivity with peptide determinants and apparently does not react with
other closely related carbohydrate antigens. All of the antibodies are somewhat
restrictive in their target specificity and may require more than one site of
modification. Despite their limitations, these antibodies have proven invaluable in
both early and ongoing studies of O-GlcNAc biology.
Several chemical approaches have also been developed to analyze 0GlcNAc residues(31S).

Alkaline l1-elimination can be used to generate

radiochemically labeled O-GlcNAc moieties (114, 299) and

introduce a

radiochemical label if borotritide is used instead of borohydride in the reduction
stage of the reaction. Another more recent approach, mild l1-elimination followed
by Michael addition with dithiothreitol (BEMAD), is useful for mass spectrometry
(312).

Bertozzi's group (306) recently developed a purely chemical means of
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detection involving the incorporation of an azido derivative of GlcNAc (GlcNAz)
into protein targets of O-GlcNAc.

Because the enzymes of O-GlcNAc

modification (OGT and O-GlcNAcase) tolerate analogs of their natural substrates
in which the N-acyl side chain has been modified to a bio-orthogonal azide
moiety (GlcNAz), cells can be metabolically labeled or the reaction can be
performed

in

vitro

with

recombinant

galactosyltransferase.

These

0-

azidoacetylglucosamine-modified proteins can be covalently derivatized with
various biochemical probes at the site of protein glycosylation using Staudinger
ligation. This strategy should have general application for both the identification
of O-GlcNAc-modified proteins and mapping protein target sites that bear 0GlcNAc modification. Because UDP-GlcNAc is incorporated into several classes
of glycoconjugates, specificity must be demonstrated with properly controlled
experiments. Tagging-via-substrate (TAS)(226) and Click-chemistry(98) also use
the same principle. These techniques are highly sensitive and especially useful
for lower molecular weight proteins.

Despite the development of such

techniques, the lack of a recognizable consensus motif somewhat complicates
the analyses of O-GlcNAc function and limits predictive capabilities.

3. E. How does O-GlcNAc signaling affect cellular function in disease?
Since its discovery two decades ago, O-GlcNAc has been implicated in a
variety of pathological processes such as neurological diseases, cancer,
diabetes, and insulin signaling. Genes encoding both OGT and O-GlcNAcase
map to chromosomal regions associated with neurodegenerative diseases.
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Neurodegenerative disorders result from disease-specific protein aggregates due
to accumulation of certain major proteins (116, 161, 287). This protein
accumulation may be due to defects in these proteins, accelerated rate of
synthesis or defects in protein degradation. Since the ubiquitin-proteosome
system (UPS) disposes of some of these protein aggregates (185, 202, 233), it is
plausible that failure of the UPS would contribute to the pathogenesis of
neurodegenerative disorders. Numerous studies have shown that proteosomal
function is controlled by post-translational modification of its cap by O-GlcNAc
(113, 279, 280, 334). Moreover, augmented O-GlcNAc modified proteosome is
less active proteosome(334). Recently, Kan et al. showed that augmented 0GlcNAc modification in the brain (with streptozotocin) reduced cerebral function
and induced neuronal apoptosis (192). Alzheimer's disease, a neurodegenerative
disease is characterized by the aggregation of
associated protein, tau in affected neurons.

~-amyloid

~-amyloid

and microtubule-

and tau proteins are 0-

GlcNAc-modified and the degree of O-GlcNAcylation has been shown to change
in Alzheimer's disease(8, 90, 91). Moreover, the gene encoding O-GlcNAcase,
the enzyme involved with the removal of O-GlcNAc modification, has been
mapped to a region on chromosome 10q24.1 linked to Alzheimer's disease (55).
Altered protein glcosylation is known to correlate with tumorigenesis, but
the role of O-GlcNAc in the pathogenesis of tumors is still to be determined.
Many oncogene and tumor suppressor gene products, such as c-Myc, SV40
large T antigen, and p53, have been shown to be modified by O-GlcNAc. The
oncogen, c-Myc is O-GlcNAc-modified at Thr-58, a known phosphorylation site.
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O-GlcNAcylation of tumor suppressor gene p53 is known to increase DNA
binding and transcriptional activity.

The O-GlcNAcylation of oncogenes and

tumor suppressor proteins emphasizes the critical roles of O-GlcNAcylation in
cancer.
The vast majority of the data amassed so far on O-GlcNAc and cellular
function are in the context of diabetes and dysregulation of insulin signaling.
There is significant evidence suggesting that prolonged augmentation of 0GlcNAc levels either via increasing HBP flux(129, 257), overexpression of
OGT(324), or inhibition of 0-GlcNAcase(307), impair insulin signaling a hallmark
of type II diabetes. Flux through HBP can be regulated by cellular glucose levels,
GFAT or glucosamine. Adipocytes and muscles cells exposed to chronic high
levels of glucose in the presence of insulin develop insulin resistance. Moreover,
inhibition of GFAT (with DON) blocked the hyperglycemia-mediated insulin
resistance while glucosamine treatment (enters HBP down stream of GFAT)
restored the insulin resistant phenotype (129, 203, 208, 210, 257). Blockade of
insulin-stimulated GLUT4 translocation and subsequent glucose uptake have
been proposed as possible mechanisms through which hyperglycemia and
glucosamine induce insulin resistance (29, 129). Direct manipulation of OGT and
GCA, the enzymes involved with the regulation of O-GlcNAc modification, is
associated with the
resistance.

pathogenesis of diabetic complications and

insulin

Interestingly, genetic studies reveal that mutation of GCA gene is

associated with susceptibility to the development of diabetes in the Mexican
American population (139, 184). In addition, nematodes (C. e/egans) expressing
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GCA null allele exhibited a phenotype metabolically similar to that of human type
II diabetes (SO). Overexpression of OGT in cardiac myocytes impaired calcium
cycling via inhibition of SERCA, a phenotype reversed by ectopic overexpression
of GCA(4S). Also, pharmacologic augmentation of O-GlcNAc signaling (via GCA
inhibition with PUGNAc) causes insulin resistance in 3T3-L 1 adipocytes (307).
Hence, alteration of post-translational protein glycosylation is influential in the
pathogenesis of insulin resistance and the development of other diabetic
complications.
This project explores the role of O-GlcNAc signaling in the pathogenesis
of acute myocardial ischemia.

It provides evidence that O-GlcNAc signaling is

endogenously recruited during acute stress events in the heart.

Moreover, it

highlights O-GlcNAc signaling as an emerging cardioprotective signal and
identifies potential mechanisms of O-GlcNAc-mediated cardioprotection.
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CHAPTER III
HYPOTHESIS AND SPECIFIC AIMS
Physiological or chemical stress normally induces signal transduction events that
end with the activation and/or production of molecules and proteins that diminish
the effects of deleterious signaling pathways (167, 172). Protein phosphorylation
is typically the mechanism associated with these signal transduction pathways
but in 2004, Zachara et al. showed that the post-translational sugar protein
modification, O-GlcNAc, may be a stress induced signal. In this study, exposing
multiple cell lines to diverse stressors (heat shock, ethanol, UV, hypoxia,
reductive, oxidative and osmotic stress), results in a rapid and global increase in
O-GlcNAc levels (332).

This response was one of the earliest responses.

Moreover, interventions that reduced O-GlcNAc levels resulted in post-stress
lethality while interventions that augmented O-GlcNAc levels resulted in more
stress tolerant cells raising the possibility that increasing O-GlcNAc modification
acts as a short-term survival signal (331, 332). In addition, it has been proposed
that stress-induced glucose uptake results in elevated pools of UDP-GlcNAc and,
hence, increased O-GlcNAc in cells(216).
O-GlcNAc is intricately linked to glucose because its donor, UDP-GlcNAc
is the end product of HBP which uses less than 5% of cellular glucose. Several
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Studies have shown that cells subjected to stress rapidly take up glucose (188,
201, 217). Moreover, this increased glucose uptake has been associated with
increased tolerance to stress either by maintaining membrane potential,
stabilizing redox state and/or maintaining cellular ATP levels(109, 188, 201, 240,
282).
In a healthy functioning adult heart, about 60-70% of myocardial energy is
obtained from the metabolism of fatty acids, while the remainder comes from
non-lipid sources like carbohydrates, ketone bodies, and amino acids (196, 247,
248). This is supported by data showing that cardiomyocytes remain viable and
beat synchronously when cultured in glucose-free media for several days(248).
Nevertheless, during ischemia or hypoxia, the primary source for maintenance of
myocardial viability is glucose (251, 252, 273). Hypoxia/ ischemia induced the
translocation of the major glucose transporter GLUT-4(281), increased GLUT-1
expression (26), and increased hexokinase activity(212). Multiple studies have
suggested that augmented glucose uptake and glycolytic flux can reduce
ischemic/hypoxic injury in cardiomyocyte in vivo or in vitro (15, 76, 236).

In fact,

Malhotra et al. showed that glucose uptake and metabolism through glycolysis
protected cardiomyocytes from hypoxia-induced apoptosis(201). Taken together,
these events serve to enhance glucose uptake and metabolism.
More interesting is the fact that glycolysis is not the only glucose metabolic
pathway implicated in glucose-mediated protection.

Studies have shown that

blocking glucose flux via the hexosamine biosynthetic pathway (HBP) using
azaserine (a GFAT inhibitor), reduced glucose-induced JNK1 activity(193), and
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ablated hyperglycemia-mediated decrease in angiotensin II induced hypertrophy
(237) resulting in decreased cell survival. The end product of HBP serves as the
monosaccharide donor for the post-translational glycosylation of proteins, 0GlcNAc, raising the possible involvement of O-GlcNAc signaling in glucosemediated cytoprotection.
Knowing that ischemia/hypoxia is a stress event, we sought to determine if
O-GlcNAc signaling is involved with the lethality associated with neonatal cardiac
myocytes subjected to oxidative stress, hypoxia-reoxygenation, ER stress and
adult mice subjected to myocardial ischemia.

Hence I proposed the general

hypothesis that O-GlcNAc signaling confers cardioprotection against acute stress
(Figure 6). After identifying potential proteins O-GlcNAc-modified in the heart, I
further hypothesized that one potential mechanism of O-GlcNAc-mediated
cardioprotection is attenuating mitochondrial death pathway. Moreover, since ER
stress is known to contribute to the pathogenesis of post-hypoxic or postischemic injury, I hypothesized that mitigating the activation of maladaptive ER
stress response is another possible mechanism through which O-GlcNAc
mediates cardioprotection.

To test this hypothesis, I addressed the following

specific aims.

Specific Aim I: Determine if O-GlcNAc modification is protective in the heart
a. Determine the role of O-GlcNAc transferase in cardiomyocytes following
hypoxia-reoxygenation and ER stress.
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b.

Determine the role of O-GlcNAcase in cardiomyocytes following oxidative
stress, hypoxia-reoxygenation, and ER stress.

Specific Aim II: To identify metabolic proteins modified by O-GlcNAc in the heart
a. Use a gel based approach to discover potential candidate proteins in
card iomyocytes
b. Incorporate a focused approach to interrogate discrete protein subsets
within mitochondria
Specific Aim III: To evaluate the influence of O-GlcNAc on mitochondrial
mediated death pathway.
a. Determine whether manipulation of O-GlcNAc signaling affects posthypoxic ROS generation
b. Determine whether manipulation of O-GlcNAc affects post-hypoxic Ca 2 +
overload.
c. Determine whether manipulation of Q-GlcNAc affects post-hypoxic
recovery of mitochondrial trans inner membrane potential.
d. Characterize potential modulation of mitochondrial permeability transition
pore.
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Figure 7. Hypothesis scheme
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CHAPTER IV
MATERIALS AND METHODS

All animals were used in compliance with the Guide for the Care and Use of
Laboratory Animals, published by the National Institutes of Health (Department of
Health and Human Services, publication NO. [NIH] 86-23). The experimental
protocol for the present study was reviewed and approved by the Institutional
Animal Care and Use Committee of the University of Louisville.

Neonatal rat cardiac myocyte isolation and culture:

Neonatal rat cardiac

myocytes (NRCMs) were isolated from 1-2 day old Sprague-Dawley rats and
cultured according to a well characterized protocol (4, 158, 290, 291). Mice were
decapitated, hearts removed, rinsed and minced in calcium- and bicarbonate-free
Hank's buffer with HEPES. The tissue fragments were digested by stepwise
trypsin (10 mL) dissociation. The dissociated cells were mixed with 7mL FBS,
and centrifuged at 180g at room temperature for 5 minutes. The pellet was
resuspended in 30mL of warm fortified DMEM containing 5% fetal bovine serum,
penicillin/streptomycin, and vitamin B12 , and centrifuged at 180g for 5 minutes.
Pellet was then resuspended in 50 mL of warm fortified DMEM, and then
preplated in 100mm dishes for one hour to allow fibroblast to adhere and enrich
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culture with myocytes. The nonadherent myocytes were then plated at a density
of 0.8-1.0x 106 cells/mL. BrdU (0.1 mmol/L) was added to the medium the first
four days of culture to inhibit fibroblast growth. The cells were maintained at 37°C
in the presence of 5% CO 2 in a humidified incubator. Twenty-four hours prior to
experimentation, medium was changed to serum-free DMEM.
Mouse genotyping: At 6-8 weeks of age, mice were ear tagged and tail snips

were taken. Total DNA was isolated from tail snips using the Qiagen DNAeasy
Tissue Kit. The DNA was stored at -20°C until PCR was performed. PCR was
performed using the Taq PCR Core Kit from Qiagen.

Mixes were created as

follows: tube 1 contained 1 IJL DNTP, 1ul of 20 IJmoi/L Primer 0lMR3203 (5'-CAT
CTC TCC AgC CCC ACA AAC Tg-3'), 1 IJL of 20 IJmollL Primer 0lMR3204 (5'gAC gAA gCA ggA ggg gAg AgC AC-3'), 10 IJL Enzyme Q, and 7 IJL water per
sample. Tube 2 contained 5 IJL 10X buffer, 0.5 IJL Taq, and 14.5 IJL water per
sample. 20 uL of each tube were added to PCR tube containing 10 IJL of purified
DNA. PCR was performed at the following conditions: 1 cycle of 94°C for 3 min,
35 cycles of 94°C for 30 sec, 61°C for 1 min and 72°C for 1 min, 1 cycle of 72°C
for 2 min then hold at 4°C ad infinitum. PCR samples were run on a 2% agarose
gel with SYBER Safe stain (Invitrogen).

Gels were visualized under UV light

using a Fuji LAS-3000 imaging system. Once the line was taken to OGT-loxP
flanked homozygosity, neonatal mouse cardiac myocytes were isolated and
cultured as described below.
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Neonatal mouse cardiac myocyte isolation and culture: Neonatal mouse
cardiac myocytes (NMCMs) were isolated from 1-2 day old homozygous 10xPflanked OGT mice using a modified protocol for NRCM isolation.

Mice were

decapitated, hearts removed, rinsed and minced in calcium- and bicarbonate-free
Hank's buffer with HEPES. The tissue fragments were digested by stepwise
trypsin (2 mL) dissociation. The dissociated cells were mixed with 3mL FBS, and
centrifuged at 180g at room temperature for 5 minutes. The pellet was
resuspended in 6mL of warm fortified DMEM containing 5% fetal bovine serum,
penicillin/streptomycin, and vitamin B12 , and centrifuged at 180g for 5 minutes.
Pellet was then resuspended in 10 mL of warm fortified DMEM, and then
preplated in 100mm dishes for one hour to allow fibroblast to adhere and enrich
culture with myocytes. The nonadherent myocytes were then plated at a density
of 0.6-1.0x 106 celis/mL. BrdU (0.1 mmol/L) was added to the medium the first
four days of culture to inhibit fibroblast growth. The cells were maintained at 37°C
in the presence of 5% C02 in a humidified incubator.

Gene transfer:

NRCMs were infected with replication-deficient adenoviruses

carrying OGT gene (AdOGT), O-GlcNAcase (Ad GCA), green fluorescent protein
(AdGFP), or empty virus (AdNull) for 48 hours as described previously(291).
Doses used include 0 and 100 multiplicity of infection (MOl).

NMCMs were

infected with replication-deficient adenovirus carrying the CRE recombinase
gene (0 or 50 Mal AdCRE) for 72 hours to remove the 10xP-flanked OGT gene
(Fgure 7). Twenty-four hours prior to experimentation, medium was changed to
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serum-free DMEM.

An initial aliquot of AdOGT and AdGCA (48) was

subsequently expanded and purified using cesium chloride gradients, yielding
adequate concentrations (10 1°_10 11 plaque forming units/milliliter) while AdCRE,
AdGFP, and AdNull were purchased from Vector Biolabs. Functional expression
was

confirmed

by

c..=J
loxP ogt

~

C\

appropriate

o

immunoblot

analysis.

Homozygous loxP
flanked OGT mouse

loxP

1

~

~~~
Neonates

Cultured Neonatal mouse
cardiac myocytes (NMCMs)
with loxP flanked OGT

NMCMs without ogt gene

Figure 8. OGT knockout protocol. Neonatal mouse cardiac myocyte (NMCM)
OGT knockout. Mice carrying 10xP flanked OGT gene were bred to
homozygousity on the C57 background. NMCMs were isolated and cultured.
NMCMs were infected with adenovirus carrying the CRE recombinase gene
(AdCRE) for 72hrs. Because CRE recombinase drives the fusion of lox P sites,
infecting NMCMs with AdCRE results in deletion of ogt gene.
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Enzyme inhibition:
ethanol),

[2H-1,

NRCMs were treated with
3-thiazine-6-carboxylic

acid,

Vehicle (0.1 % OMSO or
2-[(4-chlorophenyl)

imino]

tetrahydro-4-oxo-3- (2-tricyclo [3.3.1.13, 7] dec-1-ylethyl-)] (i.e. compound 4 or
TT04: 1 molll) or 3(2H)-bensoxazolecarboxylic acid, 5-chloro-2-oxo-phenyl ester
(i.e. compound 5 or TT40: 10 I-Imol/l) dissolved in OMSO (96) prior to
hypoxia/reoxygenation or two hours before protein harvest for western blotting to
inhibit OGT.

TT04 and TT40 compete with UOP-GlcNAc for binding to OGT

thereby blocking the addition of GlcNAc to protein (96). TT04 is toxic to cells
above 1 I-Imol/l during normoxia, thus the reason for short treatment time and
concentrations used. O-GlcNAcase activity was blocked using O-(2-acetamido-2deoxy-d-glucopyranosylidene) amino-N-phenylcarbamate (111, 317) in 0.1 %
ethanol

(i.e.,

PUGNAc:

200l-lmol/l,

overnight)

and

subjected

to

hypoxia/reoxygenation or total protein isolated for western blotting. Sample size
was equal to six per group per treatment.

RNA Interference: Cultured NRCMs were transfected with short interfering (si)
RNA

directed

against

OGT

(30nmol/l,

siRNA

10

#

173150;

5'-

GCCUGACAAUACUGGUGGUGUUtt-3'), short interfering (si) RNA directed
against O-GlcNAcase (60nmol/l, siRNA 10 # 190811; with sense strand 5'GCAACUUAUGACUCCAUCtt-3'

and

antisense

strand

3'-

GAUGAGAGUCAUAAGUUGCtc-5') or control sequence fluorescently tagged as
a non-silencing control (C/ M3-labeled negative control, Applied Biosystems).
Myocytes were transfected with Ambion's SiPORT NeoFX transfection reagent
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according to manufacturer's instructions.

Thirty-six or seventy-two hours

following transfection, myocytes were subjected to H/R or whole cell Iysates were
harvested for assessment of OGT protein, O-GlcNAcase and O-GlcNAc levels as
described below. Sample size is equal to six per group per treatment.

ER stress induction: Normoxic NRCMs treated as mentioned above were
subjected to ER stress by treatment with 1 ~g/mL of Brefeldin A (BfA) or 0.5
~g/mL

of Tunicamycin (TM) for 24 hours. TM inhibits N-glycosylation of nascent

ER proteins by preventing UDP-GlcNAc-dolichol phosphate GlcNAc-phosphate
transferase activity (72) while BfA interferes with anterograde protein transport
from the ER to the Golgi apparatus by inhibiting transport in Golgi, which leads
to proteins accumulating inside the ER (81).

Reverse Transcription Real-Time peR:

DNA-free total RNA was extracted

with Trizol reagent (Invitrogen) from NRCMs treated with AdGFP (100 Mal, 48
hours), AdOGT (100 Mal, 48 hours), AdGCA (100 Mal, 48 hours), Vehicle or
PUGNAc

(200~mol/L,

overnight). Manufacturer's instructions.

Total RNA

concentration was determined by measuring the absorbance at 260nm (A260).
The ratios of readings at 260nm and 280nm (A260/A280) or 260nm and 230nm
(A260/A230) provided an estimated of protein/ phenol and DNA contaminants
respectively. For purity, the ratio A260/A280 should be above 1.8 and the A260/A230
ratio should be a close to 2. Total RNA (1 I-Ig) according was subjected to reverse
transcriptase reaction to synthesize the cDNA using IScripFM cDNA synthesis kit
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(BioRad). Sequences for GCA, S001, S002, GPX, Cat, 18s, and GAPOH, used
are shown in Table 3. The relative levels of GCA, S001, S002, GPX, Cat, 18s
and GAPOH mRNA transcripts were quantified by real-time PCR using SYBR®
Green (Applied Biosystems). The data generated were normalized to GAPOH or
18s threshold cycle (C T ) values by using the MCT comparative method (194).

Table 3: Primers for real time peR
gene

Sense (5'-3')

Anti-sense (3'-5')

gca

tggaagaccttgggttatgg

tgctcagcttcttccactga

sod1

ccactgcaggacctcatttt

caatcacaccacaagccaag

sod2

ggccaagggagatgttacaa

gaaccttggactcccacaga

gpx

tcagttcggacatcaggaga

cattcacctcgcacttctca

catalase

gtggttttcaccgacgagat

catgtcagggtccttcaggt

gapdh

tgatgacatcaagaaggtggtgaag

tccttggaggccatgtgggccat

18s

aaacggctaccacatccaag

cctccaatggatcctcgtta

Protein expression:

Total cellular proteins were isolated from NRCMs as

follows. NRCMs were washed with PBS, harvested in ice-cold lysis buffer
(containing 68 mmol/L sucrose, 200 mmol/L mannitol, 50 mmol/L KCI, 1mmol/L
EGTA, 1mmol/L OTA and 5 mmol/L HEPES) with freshly added 0.2 j.lmol/L OTT,
0.1v/v% protease inhibitor stock, 0.4% (v/v) NP-40, 0.4% (v/v) Triton-X and post
translational modification inhibitor stock.
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Extracts were sonicated and the

resulting Iysates centrifuged at 15000xg for 5 minutes at 4°C to remove cell
debris. Forty micrograms of protein (according to Bradford assay) was applied to
each lane of a 6% SOS-PAGE electroblotted onto PVOF membranes for 0GlcNAcase, while fifty micrograms of protein was applied to each lane of a 412% or 10% gradient NuPAGE Bis-Tris gel (Invitrogen) or 7% NuPAGE Trisacetate gel (Invitrogen) and electroblotted onto nitrocellulose membranes
(Invitrogen) for OGT, O-GlcNAc levels and a-tubulin. Reagent-grade nonfat milk
(BioRAO) 5% (w/v) in Tris buffered saline was used for blocking.

Blots were

incubated with anti-OGT (1 :1000, SIGMA), anti-O-GlcNAcase (1 :200, a gift from
Or Zachara of Johns Hopkins), anti-O-GlcNAc antibodies (1 :1000 CTO 110.6;
Covance or 1:2000 RL2; Affinity BioReagents), anti-Grp 94 (1:1000, SCBT), antiGrp 78 (1:1000, SCBT), anti-PARP (1:1000, SCBT), anti-CHOP (1:1000, SCBT),
anti-calreticulin (1: 1000, SCBT) or anti-a-tubulin (1: 1000, SCBT), as primary
antibodies for 12 minutes at 25°C or overnight at 4°C. Blots were then incubated
for 12 minutes or one hour with 0.051-Jg/mL of appropriate HRP-conjugated
secondary antibody (goat anti-rat IgG, goat anti-rabbit IgG, goat anti-mouse IgM,
goat anti-mouse IgG, donkey anti-goat IgG or anti-chicken IgG) and detected
with an enhanced chemiluminescent detection system (Pierce).

Glycoprotein staining: Total cellular protein was isolated from NRCMs treated

with either Vehicle, OGT inhibitor (1l-Jmol/L TT04) or infected with adenovirus
overexpressing OGT as described above. Following SOS-PAGE, gels were fixed
by incubation in 50% methanol and 5% glacial acetic acid for 2 hours at 25°C.
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The fixed gels were then washed by gentle agitation three times with 3% glacial
acetic acid solution for 10minutes, oxidized with periodic acid for one hour at
room temperature, stained with Pro-Q emerald for 1hour in the dark and imaged
using a 488 laser and S20 /BP 40 emission filter on TYPHOON 9400.

Enzymatic labeling of O-GlcNAc-modified proteins:

O-GlcNAc modified

proteins were labeled using Invitrogen's Click-iT enzymatic labeling kit according
to manufacturer's instructions (Figure 8).

Detergents were precipitated out of

200IJg whole cell lysate (n=6/group) or SOIJL of immunoprecipitated protein
(VDAC

or

O-GlcNAc

modified

proteins)

using

the

chloroform/methanol

precipitation method by adding 600 IJL of methanol, 1S0 IJL of chloroform and
400 IJL of distilled water and centrifuging at 14000g for Smins at 4°C.

The

interface layer containing the protein precipitate was washed twice with methanol
and centrifuged at 14000g for Smins at 4°C.

The resulting pellet was then

covered with lint-free paper and allowed to dry for 1Smins in fume hood.

The

dried pellet was resuspended in 40 IJL of 1% SDS and 20mM HEPES buffer pH
7.9, boiled at 90°C for Smins, vortexed briefly and allowed to coolon ice for
3mins. 49 IJL of distilled water, 80 IJL of labeling buffer and 11 IJL of MgCI2 were
added and the mixture vortexed briefly. 10 IJL of UDP-GaINAz (azide-modified
UDP-N-Acetylgalactosamine) and 7.S IJL of mutant

~-1-4-galactosyltransferase

were added. The mixture was vortexed briefly and incubated at 4°C overnight.
The next day, the GalNAz-labeled O-GlcNAc-modified protein mixture was
precipitated

using

the

chloroform/methanol
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precipitation

method

and

resuspended in 50 IJL of buffer containing 1% SOS, 50mM Tris-HCI, and pH 8.
The azide-labeled proteins were tagged with a fluorescent dye, TAMRA, by
adding 100 IJL of TAMRA in 2x click-iT reaction buffer, 10 IJL of distilled water, 10
IJL of CUS04, 10 IJL of click-iT reaction buffer additive 1 and 20 IJL of Click-iT
reaction buffer additive 2. The mixture was vortexed for 5secs after the addition
of each component.

The mixture was then rotated for 1 hour at 4°C for the

conversion of the azide group to a stable triazole conjugate. 25mM DTT was
added, incubated at 4°C for 15mins to stop the reaction and proteins precipitated
using the chloroform/methanol precipitation method. The dried-labeled protein
sample was resuspended in SOS-PAGE buffer for electrophoresis. The gel was
then imaged by excitation using a 532nm laser on a TYPHOO 9400 imager.

SYPRO Ruby staining: Gels were stained for total protein using SYPRO ruby

gel stain according to manufacturer's instructions. Briefly, gels were first washed
3 times using distilled water, fixed by incubation in 50% methanol and 5% glacial
acetic acid for 15 minutes at 25°C, and washed by gentle agitation three times
with distilled water for 10minutes.The fixed gels were then rapid stained with
SYPRO ruby for 1hour in the dark by microwaving and agitating for 30 seconds,
microwaving for 30 seconds and agitating for 5minutes and microwaving for 30
seconds and agitating for 23 minutes. The stained gels were then destained by
gentle agitation

in 7% glacial acetic acid and 10% methanol solution for

30minutes, washed by gentle agitation three times with distilled water for 5
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minutes, and imaged using a 488 laser and 610 IBP 30 emission filter on
TYPHOON 9400.

Gal-T1
~,

I', ,,
Whole cell lysate

Incubate
,)

~~~

)

TAMRA-alkyne

UDP-GaINAz

UDP-GaINAz caps O-GlcNAc
molecules on modified proteins

J
Gel electrophoresis

/
Excite TAMRA to detect O-GlcNAct - ( - -- - modified VDAC

Migration

Figure 9. Enzymatic labeling of O-GlcNAc-modified proteins.
Exogenous
galactosyltransferase (Gal-T1) was used to cap O-GlcNAc molecules on modified
proteins with azide-modified galactosamine (UDP-GaINAz) overnight. GalNAz
capped proteins were then incubated with a fluorescently tagged alkyne
(TAMRA-alkyne) to convert the "azide" group into a stable triazol conjugate.
Proteins were then separated by SDS-PAGE and imaged on TYPHOON 9400.

Identification of O-GlcNAc-modified Proteins: Proteins from Vehicle and
PUGNAc-treated samples were precipitated with 10% trichloroacetic acid (v/v)
and centrifuged at 14,055 x g for 15 minutes at 4°C. The protein pellets were
washed with acetone and dried under a gentle stream of nitrogen gas. Two-
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dimensional electrophoresis (20E) sample buffer (20 mmolll Tris, pH 6.8,
containing 8 molll urea, 2% CHAPS, 1 mmol/l EOTA, and 50 mmol/l OTT) was
then added and proteins were allowed to solubilize for 2 hours at room
temperature with gentle vortexing. Samples were again centrifuged at 14,055 x g
for 15 minutes at 4 °C and the protein concentration in the supernatant was
assayed by a modified method of Bradford using bovine serum albumin in 8mol/l
urea as a standard. OTT was added to a final concentration of 50 mmol/l,
ampholytes were added to 1%, and 40 IJg of protein from the Vehicle and
PUGNAc-treated samples were loaded for passive rehydration (12 hours
incubation) onto 3-10 Nl and 7-10 IPG strips (Bio-Rad). The proteins were
isoelectrically focused (Figure 9) for 26000 V/hrs at 25°C and strips were then
equilibrated with base rehydration buffer containing OTT and iodoacetamide,
respectively. IPG strips were then loaded on a 12% polyacrylamide gel and
electrophoresed for 90 minutes at 140 V for protein separation in the second
dimension.

Proteins

were

then

transferred

to

PVOF

membranes

by

electroblotting overnight at 30 mA. Parallel gels were silver-stained using the
EMBl silver-staining protocol. For western analysis, O-GlcNAc-modified proteins
were probed using 4 IJg/ml anti-O-GlcNAc monoclonal antibodies (CT0110.6)
followed by 0.1 IJg/ml goat anti-mouse secondary antibodies. Membranes were
developed using ECl Plus reagents and analyzed with a Typhoon 9400 Variable
Mode Imager (Amersham Biosciences).

To obtain peptides for MS analysis,

protein spots of interest were excised from parallel silver-stained gels and
digested with trypsin using a modified version of the method described by Jensen
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et 81(150). Briefly, the excised gel pieces were incubated for 15 minutes in 100

mmollL NH 4 HC03 and 50% acetonitrile and dried by vacuum centrifugation.
Proteins were then reduced by incubation with 20 mmollL OTT at 56°C for 45
min, followed by alkylation with 65 mmollL iodoacetamide in the dark at room
temperature for 30 min. After alkylation, gel pieces were incubated for 15 min in
50 mmol/L NH 4 HC03 and 50% acetonitrile and dried by vacuum centrifugation.
Proteins were hydrolyzed by incubation in 20 ng of modified trypsin (Promega)
per ml at 3rC overnight. Trypsin-generated peptides were applied on stainless
steel targets by thin-film spotting using a-cyanohydroxycinnamic acid (Aldrich) as
a matrix.

Mass spectral data were obtained with a TOF-Spec 2E instrument

(Micromass) and a 337 nm N2 laser at 20 to 35% power in the reflector mode.
Spectral data were obtained by averaging 10 spectra, each of which was the
composite of 10 laser firings. Mass axis calibrations were accomplished by using
peaks from tryptic auto-hydrolysis. Peptide masses obtained by MALOI-TOF/MS
analysis were analyzed with Protein Probe software (MassLynx) to identify intact
proteins. Additionally, the National Center for Biotechnology Information (NCBI)
database was also used for protein identification(238).

Peptides displaying

masses consistent with O-GlcNAc modification (monoisotopic mass
were ascribed as potentially modified protein fragments.
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Figure 10. Protocol for identifying O-GlcNAc modified proteins by 2-D gel
electrophoresis followed by MALDI-TOF.
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Mitochondrial isolation: C57BLl6 mice were injected (intraperitoneal) with
Vehicle (0.1 % w/v DMSO or 0.1 % ethanol), 10 mg/kg TT04, or 50mg/kg of
PUGNAc. After 18 h, the mice were anesthetized with 100 mg/kg pentobarbital.
Hearts were harvested, immediately rinsed with PBS, and placed in Kontes Duall
homogenizer containing 4 mL sucrose buffer A (300 mmollL sucrose, 10 mmol/L
Tris-HCI, 2 mmollL EGTA and 5 mg/mL BSA, pH 7.4) on ice. Hearts were
homogenized using 12 strokes. The homogenate was centrifuged at 2000 xg for
2 min at 4 °C to remove cell debris. The supernatant was further centrifuged at
10,000 xg for 5 min 4 °C to sediment impure mitochondria. Mitochondria were
washed twice with 1 mL of sucrose buffer A (minus BSA)(92) and purified by
adding 19% Percoll and centrifuging at 14,000 xg for 10 min at 4 °C.
Mitochondrial pellet was washed twice with 0.5 mL of sucrose buffer B
(300 mmollL sucrose, 10 mmollL Tris-HCI, pH 7.4)(103). Purified mitochondrial
pellet was resuspended in 0.5 mL of sucrose buffer B. 100l-iL of mitochondrial
stock was used for protein concentration determination using BIO-RAD protein
assay buffer according to the Bradford method. Adult mouse hearts were used to
confirm the insights from the neonatal rat cardiomyocytes in the adult
myocardium, and more importantly, because of the relatively high yield of intact
mitochondria from the adult mouse heart.

Co-immunoprecipitation: Co-immunoprecipitation was performed with Protein
G immunoprecipitation kit (Sigma) according to manufacturer's instructions on
adult mouse cardiac mitochondrial proteins from DMSO, TT04 (OGT inhibitor),
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HCI or PUGNAc treated mice as shown on Figure 10. Briefly, 5
GlcNAc antibody (RL2) or 10
buffer were added to 50
4 °C for 1 h.

50

~L

~L

~L

~L

of the anti-O-

of the anti-VDAC antibody and 245

~L

of 1x IP

of sample and rotated in an end-to-end fashion at

of washed Protein-G-sepharose beads was added to

antibody-sample mixture and rotated in a head-to-tail fashion at 4 °C overnight.
The antibody-sam pie-bead mixture was then washed five times with 300

~L

of 1x

IP buffer and once with 0.1x IP buffer centrifuging at 12,000 000 xg at 4 °C for
30 s between washes. 1x sample buffer, reducing agent and 1x TBS were added
and the mixture was heated at 95 °C for 5 min.

Samples were then

immunoblotted for VDAC using anti-VDAC (1 :2000, Santa Cruz) or O-GlcNAc
using RL2 (1 :1000, Affinity BioReagents). Standard densitometry was performed
and the value for the Vehicle (DMSO or HCI) group was set at 100%. All samples
were normalized to their total VDAC levels (which were not different between the
two groups).

Antibody (antiVDAC or antiO-GlcNAc)

Antibody binds to
specific protein
proteins
by boili n g

J

Antigen-antibody
complexes
bound to beads

Gel
electrophoresis

1

~

Migration

Proceed w it h W este r n b l otting

Figure 11. Immunoprecipitation protocol.
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Densitometry:

Densitometry

was

performed

using

non-saturated

chemiluminescent membranes exposed and quantitated using Fuji LAS-3000
bio-imaging analyzer. Multiple exposures from every experiment were used to
confirm that the signal was within the linear range. Densitometric analysis of 0GlcNAc levels using CTD 110.6 and RL2 antibodies were performed on the
entire lane.

O-GlcNAc levels were normalized to the appropriate control

(Ponceau stain), and then expressed as a percentage of control (set at 100%).

In vitro hypoxia-reoxygenation injury in cardiac myocytes: Cardiac myocytes
were subjected to hypoxia

using Esumi lethal ischemic media, pH 6.2

(containing 117 mmol/L NaCI, 12 mmol/L KCI, 0.9 mmol/L CaCI 2, 0.49 mmol/L
MgCI 2, 4 mmol/L HEPES, 20 mmol/L sodium lactate, and 5.6 mmol/L L-glucose)
by sealing the plated myocytes in humidified hypoxic chambers (BillupsRothenberg, Inc) (164), flushing each chamber with a gas mixture consisting of
5% C02 and 95% N2 for fifteen minutes, and incubating the hypoxic chamber in a
modular incubator at 37°C for three hours.

Following hypoxia, the media was

changed to 1x Esumi control media (pH 7.4, 137 mmol/L NaCI, 3.8 mmol/L KCI,
0.9 mmol/L CaCI 2, 0.49 mmol/L MgCb, 4 mmol/L HEPES, and 5.6 mmol/L Dglucose) and culture dishes reoxygenated for one or six hours in the modular
incubator or on the fluorescent microscope during imaging as appropriate.
Similarly treated NRCMs were subjected to four or 9 hours of normoxia in 1x
Esumi control media to serve as normoxic/aerobic controls.
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Cell death: Cell death was assessed for NRCM treated as mentioned above and
subjected to hypoxia/reoxygenation by measuring normoxic or post-hypoxic LDH
release using a commercially available kit (Sigma). Data was expressed as LDH
release relative total LDH in the cells and normalized to the appropriate controls
(1 hr reoxygenation data) or normoxic untreated control (for 6hrs reoxygenation
data). Similarly treated NRCMs were stained with the fluorescent DNA-binding
dyes Hoechst 33342, 5l-1g/mL and propidium iodide, 51-1g/mL (Invitrogen) during
the last 30 minutes of reoxygenation(19).

The stained nuclei were then

visualized using a 20x objective on a Nikon-TE2000E2 fluorescence microscope
and Xcite 120 Fluor light source (level of 12%). Filters used included 350/50 nm
excitation and 470/40 nm emission filters for Hoechst and 560/40 nm excitation
and 630/60 nm emission filters for PI.

Neutral density filter setting was set at

ND4 and binning of 2x for all image acquisition. Exposure duration was set at
100ms for Hoechst and 200ms for PI. Four fields per treatment were counted
and data were expressed as % PI positive nuclei/total nuclei.

Because the

nuclear stain Hoechst 33342 is membrane permeable, it was used to determine
total cells in each field and not as an index of apoptosis. Sample size of at least
four per group was used.

Apoptosis: Apoptosis was assessed by measuring Caspase 3/7 activity in whole
cell Iysates using Caspase Glo kit (PROMEGA) according to manufacturer's
instructions.

Briefly, equal volumes of whole cell lysate (50l-lg) and caspase

reagent were mixed and incubated in the dark for one hour at room temperature.
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Bioluminescence was measure using Modulus luminometer (Turner Biosystems)
and expressed in relative luminescent units (RLUs). Sample size is equal to at
least five per group per treatment.

Fluorescence

Microscopy:

NRCMs

were

imaged

in

imaging

medium

(Dulbecco's Modified Eagle Medium (with HEPES and minus phenol red and
pyruvate). Images were captured using a Photometric CoolS NAP ES camera
attached to a Nikon-TE2000E2 fluorescence microscope with a T-PFS Perfect
Focus Unit all controlled with MetaMorph 6.3r2 software. The Perfect Focus
System was used to prevent minute defocusing caused by changes over time
during time-lapse imaging. Xcite 120 Fluor light source (level of 12%) was used
and a Plan Apo 60xA/oil (NA=1.4) objective were used for magnification. Neutral
density filter setting was set at ND4 and binning of 2x for all image acquisition.
Images were captured every 90 seconds for 60 minutes. Exposure duration was
set at 100ms for all fluorescent dyes except for rhod-2 which was set at 50ms.
Excitation and emission filters varied depending on the fluorescent dye as
mentioned below.

Assessment of Calcium Overload: NRCMs treated with AdGFP, AdNull,
AdOGT, AdGCA, vehicle, or PUGNAc were loaded with 2j.JmollL of rhod-2(290,
291) (used to assess mitochondrial calcium, Invitrogen) and subjected to 3 hours
of hypoxia. Calcium levels were assessed by following the changes in rhod-2
fluorescence during reoxygenation using time-lapse fluorescent microscopy.
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Imaging was initiated during reoxygenation by exciting rhod-2 through 560/28 nm
and 646/38 nm emission filter. All experimental groups were repeated in six
separate NRCM cultures.

Assessment of reactive oxygen species (ROS) production: ROS levels were
assessed in NRCMs using time-lapse fluorescence microscopy by following the
changes in 5-(and-6)-carboxy-Z,T-dichlorodihydrofluorescein diacetate (DCF)
fluorescence(291). NRCMs treated with AdNull, AdOGT, AdGCA, Vehicle, or
PUGNAc were loaded with 2IJmoi/L DCF and subjected to 3 hours of hypoxia as
mentioned above.

During reoxygenation, imaging was initiated immediately by

exciting DCF through 470/40 nm bandpass filter and emission through 522/40
nm bandpass filters.

All expmimental groups were repeated in at least four

separate isolations.

Assessment of mitochondrial membrane potential:

Using time-lapse

fluorescence microscopy (4, 5, 158, 290, 291), detection of mitochondrial
membrane

potential

changes

were

performed

by following

changes

in

tetramethylrhodamine methyl ester (TMRM) fluorescence. NRCMs treated with
AdGFP, AdOGT, AdGCA, vehicle, PUGNAc, Control siRNA or GCA siRNA were
loaded with 100 nmol/L TMRtvl and subjected to 3 hours of hypoxia.

Imaging

was initiated during reoxygenation by exciting TMRM through a 546/11 nm
bandpass filter and emission assessed through a 567/15 nm bandpass filter.
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Exposure duration was set at 100ms and all experimental groups were repeated
in at least four separate isolations.

Mitochondrial

swelling

assay:

The

performed similar to previous reports.

mitochondrial

swelling

assay

was

Two mg/ml cardiac mitochondria from

Vehicle- (0.1 % DMSO or 0.1 % ethanol), TT04- (OGT inhibitor), or PUGNAc(GCA inhibitor) treated mice in buffer B was loaded on a 96-well plate and
allowed to warm to room temperature. CaCI 2 (100 jJmol/L) was used to induce
mitochondrial

swelling

and

the

spectrophotometrically at 520 nm.

change

in

absorbance

measured

A decrease in absorbance indicated an

increase in swelling (i.e. mitochondrial permeability transition pore opening).

Murine in vivo ischemia-reperfusion: Three- to four-month-old male SV129
(mean body weight 25±1 g) were randomized to PUGNAc or isovolumetric
Vehicle treatment groups.

Mice were subjected to in vivo coronary artery

ischemia-reperfusion for assessment of O-GlcNAc levels or myocardial infarct
size according to well characterized protocol (Figure 11 )(156, 158). Mice were
anesthetized with intraperitoneal injections of ketamine hydrochloride (50 mg/kg)
and sodium pentobarbital (50 mg/kg).

The animals were then attached to a

surgical board with their ventral side up.

The mice were orally intubated with

polyethylene (PE)-60 tubing connected to a rodent ventilator (Harvard Apparatus)
with tidal volume and breathing rate set by standard allometric equations. The
mice were supplemented with 100% oxygen via the ventilator side port. Body
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temperature was maintained between 36.5 and 37.5 using a rectal probe and a
heat lamp.

A left thoracotomy was performed using a thermal cautery, and the

proximal left main coronary artery was visualized with the aid of a dissecting
microscope and completely occluded for 40 minutes with 7-0 silk suture mounted
on a tapered needle (8V-1, Ethicon). After 40 minutes, the suture was removed
and reperfusion was initiated and visually confirmed. The chest was closed in
layers using 4.0 silk suture.

The skin was closed using 4-0 nylon suture.

Ketoprofen was given as analgesia prior to closing the chest. Upon recovery of
spontaneous breathing, mice were removed from the ventilator, extubated and
allowed to recover in a warm, clean cage supplemented with 100% oxygen.
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Figure 12. Murine myocardial ischemia-reperfusion protocol. A - 40mins of left
anterior descending coronary artery ligation_ B - Suture cut and reperfusion
initiated. C - Reocclusion of LAD_ D - Injection of Evans blue dye into the right
carotid artery to delineate the ischemic zone and the non-ischemic zone. EHeart cross sections incubated in TTG to delineate viable and non viable tissue.
NEG: necrotic tissue and NIZ: non-ischemic zone.

Myocardial ischemic/non-ischemic zone determination: Following 40minutes
ligation of left anterior descending coronary artery in G57BL6 mice described
above , reperfusion was initiated. After 0, 1, 4 and 24 h of reperfusion , the mice
were anesthetized with isoflurane. A tracheotomy was performed and mice were
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ventilated as described above.

A catheter (PE-10 tubing) was placed in the

common carotid artery to allow for Evans blue dye injection.

A median

sternotomy was performed, and the left main coronary artery was relegated in
the same location as before.

Evans blue dye (1.2 ml of a 2% solution) was

injected into the carotid artery catheter into the heart to delineate the ischemic
zone from the non ischemic zone (Figure 11). The heart was rapidly excised and
serially sectioned along the long axis in 1-mm-thick sections. With the aid of a
dissecting microscope, the non-ischemic and ischemic zone was separated and
O-GlcNAc levels were assessed.

Myocardial infarct size determination: Myocardial infarct size was determined
according to well characterized protocol (153, 155). After 24 h of reperfusion, the
mice were anesthetized as with isoflurane and Evans blue dye (1.2 ml of a 2%
solution) used to delineate the ischemic zone from the non ischemic zone as
described above. The heart was rapidly excised and serially sectioned along the
long axis in 1-mm-thick sections, which were then incubated in 1.0% 2,3,5triphenyltetrazolium chloride for five minutes at 3rC to demarcate the viable and
nonviable myocardium within the risk zone (Figure 11). Digital pictures of the
basal of each section were taken. Each of the five 1-mm-thick myocardial slices
was weighed. A blinded observer assessed the areas of infarct, risk, and nonischemic zone using computer-assisted planimetry (Image J, version 1.38x).
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Evaluation of blood pressure, heart rate, and left ventricular function: In
order to assess the closed-chest hemodynamic status, mice were anesthetized
with

ketamine (50 mg/kg,

intraperitoneal) and

pentobarbital

(50 mg/kg,

intraperitoneal) and supplemented with oxygen via a nasal cone. A fluid-filled
polyethylene catheter was inserted into the right common carotid artery and
advanced to the aorta left ventricle via (197).

Data were recorded for 10

seconds. Offline assessment of these data yielded mean arterial blood pressure,
and heart rate (HR). The catheter was then advanced through the aortic valve
into the left ventricle (LV). Data were recorded for 10 seconds. In vivo
transthoracic echocardiography of the left ventricle using a 15 MHz linear array
transducer (15LBs) interfaced with a Sequoia C512 (Acuson) was performed
(154, 156).

Ventricular parameters were measured according to the leading-

edge technique.

M-mode (frame rate=30 Hz; sweep speed=200 mm/s)

echocardiograms were captured from short-axis views of the LV at the midpapillary level. Data for each animal were calculated from at least 10 seconds of
chart recording.

All data were calculated from 10 independent cardiac cycles

per experiment. Short axis views at the mid papillary level yielded left ventricular
(LV) end diastolic diameter (ED D), end systolic diameter (ESD), heart rate (HR),
and fractional shortening (%FS). LV fractional shortening (LVFS) was calculated
according to the following equation: LVFS= ([LVEDD-LVESD]/ LVEDD)x100.

Cardiac troponin-I assessement: cardiac Troponin-I release was measured in
plasma from mice subjected to sham surgery or ischemia-reperfusion protocol
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described above according to manufacturer's instructions.

First, a 1:4 dilution of

plasma samples in plasma diluents was made and loaded on to a 96 well plate in
triplicate. Diluted plasma samples were allowed to react simultaneously with two
affinity purified antibodies (one used for solid phase immobilization and the other
and conjugated to HRP) on the microtiter wells by incubating plate at room
temperature on a plate shaker. Wells were washed with water to remove any
unbound HRP-conjuated antibody.

HRP substrate, tetramethylbezidine was

added and plate incubated for 20 minutes at room temperature fordevelopment
of color.

1mol/L Hel was added to each well to stop color development and

absorbance measured on a spectrophotometer at 450nm. cTnl concentration of
the samples were determined from standard curve and in ng/mL.

Statistical analysis: Data were analyzed using GraphPad Prism 4 software.
One-way ANOVA was employed for three or more experimental groups and
Dunnett's t tests for post hoc analysis.

Unpaired student's

t test

was used to

analyze data containing two experimental groups. Data are reported as
mean ± standard error of the mean with differences between treatment groups
accepted as significant when p < 0.05.
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CHAPTER V
RESULTS

A. O-GlcNAc levels are altered following oxidative stress: O-GlcNAc levels
were assessed via Western blot analysis in isolated cardiomyocytes treated with
Vehicle or PUGNAc (a GCA inhibitior) and exposed to various durations of
hydrogen peroxide (H 2 0 2 , 0.1 mmol/L) in serum-free media.

Cardiomyocytes

experience a significant (p<0.05) decrement in O-GlcNAc levels at about 40
minutes (Figure 12A).

Myocytes treated with PUGNAc showed markedly

(p<0.05) higher levels of O-GlcNAc throughout the time course compared with
Vehicle-treated myocytes (Figure 12A).

Furthermore, the oxidative stress-

mediated decrement in O-GlcNAc levels was retarded in the PUGNAc- compared
with the Vehicle-treated group (Figure 12A). To determine whether reversal of
the decrement in O-GlcNAc levels could attenuate cell death, cardiomyocytes
were treated with PUGNAc or Vehicle, exposed to H2 0 2 , and coincubated with
propidium iodide and annexin V. At the end of 150 minutes of H2 0 2 exposure,
the percentage of propidium iodide-positive cells was Significantly (p<0.05)
augmented compared with control (Figure 128).

Moreover, exposure to H2 0 2

induced a significant (p<0.05) increase in annexin V fluorescence positivity
compared with control (Figure 12C). PUGNAc treatment significantly (p<0.05)
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attenuated H2 0 2-induced cell death according to PI and annexin V positivity.
Saponin permeabilization was used at the end of the experimental protocol to

•

confirm equal numbers of cells per field (Figure 128).
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Figure 13. Effects of augmented O-GlcNAc levels on oxidative stress-induced
cardiomyocyte death. A) Representative immunoblot (18) of time course of 0GlcNAc levels in cardiac myocytes treated with Vehicle or PUGNAc and
subjected to oxidative stress for 60 minutes (n=4 per group). O-GlcNAc levels
are significantly elevated in PUGNAc-treated myocytes compared with Vehicle.
8) After 150 minutes of oxidative stress, most Vehicle-treated myocytes become
PI positive, a phenomenon inhibited by PUGNAc (n=3/group). Representative
confocal images of myocytes from each treatment group at the end of the
experiment (pre-saponin) or after saponin permeabilization, indicating equivalent
number of cells per field. C) During the time course of oxidative stress, annexin
V positivity increases in Vehicle-treated myocytes, an effect attenuated by
PUGNAc. Representative confocal images of myocytes from each treatment
group at the end of the experiment (n=3/group).
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B. O-GlcNAc levels are altered following hypoxia-reoxygenation: To
determine if O-GlcNAc levels change during hypoxia and reoxygenation, isolated
neonatal rat cardiac myocytes (NRCMs) were subjected to hypoxia and
reoxygenated for different durations (0, 1 and 6 hours).

Hypoxia significantly

decreased O-GlcNAc levels compared to normoxia (Figure 13A-B).

During

reoxygenation, we observed a time dependent increase in O-GlcNAc levels
peaking after 6 hours (Figure 13A-B) and falling to minimal levels by 18 hours of
reoxygenation (data not shown).
Hypoxia damaged cardiac myocytes as reflected in increased posthypoxic LDH release compared to normoxia. Reoxygenation further exacerbated
the hypoxia-mediated myocytes injury mirrored by the time dependent increase
in post-hypoxic LDH release for hypoxic myocytes compared to normoxia (Figure
13C).
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Figure 14. Effects of hypoxia-reoxygenation on O-GlcNAc levels. Myocytes
were subjected to hypoxia for three hours and reoxygenated for zero, one or six
hours. O-GlcNAc levels were assessed on whole cell Iysates or cell injury
B)
assessed by measuring post-hypoxic LDH release in the media.
Representative immunoblots of time course of O-GlcNAc levels in cardiac
myocytes. B) Densitometric quantification of O-GlcNAc immunoblots expressed
as percent of normoxic control. C) Hypoxia induced cell injury according to posthypoxic LDH release.

76

C. ROLE OF OGT IN POST -HYPOXIC CARDIOMYOCYTE INJURY
C.1. OGT overexpression attenuates post-hypoxic cardiac myocyte death:
Adenovirus carrying the OGT gene was used to study gain-of-function for 0GlcNAc transferase (AdOGT). Forty eight hours after infecting isolated neonatal
rat cardiac myocytes (NRCMs) with AdOGT, total cellular proteins were
harvested and OGT protein and O-GlcNAc levels assessed via western blot
analysis. Infection of NRCMs with AdOGT augmented OGT levels (349 ± 86% of

o MOl,

n=3/group, Figure 14A).

Assessment of the functional readout, 0-

GlcNAc, showed significant (p < 0.05) increase in O-GlcNAc levels (145 ± 19% of

o

MOl, n>/=6/group, Figure 148). To confirm this finding, two additional

approaches were used. First, the same samples were evaluated using another
O-GlcNAc antibody (RL2), which showed a significant (n=5/group, p < 0.05,
Figure 148) increase in O-GlcNAc levels at 100 MOl compared to 0 MOl AdOGT.
Second, additional samples were prepared for evaluation using a non-immune
technique (enzymatic labeling of O-GlcNAc with TAMRA fluorophore; i.e. clickchemistry based approach). The enzymatic labeling technique also showed a
significant augmentation of O-GlcNAc levels with 100 MOl AdOGT (155 ± 9%)
compared to 0 MOl AdOGT (Figure 148). Immunoblots/gels for O-GlcNAc levels
show multiple positive bands because O-GlcNAc is a post-translational
modification, not a single protein (Figure 148).

In addition to the significant

increases in O-GlcNAc levels, there was no significant difference in total
glycoprotein levels following OGT overexpression according proQ emerald
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staining (Figure 14C). Equal protein loading was confirmed by densitometric
analysis of Ponceau-stained membranes or SYPRO ruby stained gels.

D)

A)

AdOGT (MOl )

*
C)

kDa
220
o

0

100

100

-1110kDa

80

20
220

50
IJ)

18: O-GlcNAc

Cii ~ 1
>Q) 0
1

...I::E

:ie
Z 0

TAMRA
GlcNAc

::=:=:::=-===:::::

150
100
80
60
50
40
30
20,-..;;:;.:,.........;

1

~~

c;>e....

o

o

150
100

50
40
30

60

B)

kDa .----:r--.:----:,-,
220

80
60

150

100

AdOGT(MOI)

OGT 1

AdOGT(MOI )

100

ProQ Emerald
staining

AdOGT (MOl)

Figure 15. Effects of OGT overexpression (using AdOGT) on post-hypoxic
cardiomyocyte injury. Myocytes were infected with AdOGT 48 hours prior to
protein harvest or hypoxia-reoxygenation. A) Summary densitometric analysis
(n=3/group) and immunoblot of OGT (using SQ17) show significant (p<0.05)
increase in OGT protein with 100 MOl compare to 0 MOl of AdOGT. B)
Densitometric analysis (n=5-6/group) and of the functional readout of OGT, 0GlcNAc. Significant increase in O-GlcNAc levels (n=6/group) is seen with the
CTD110.6 and RL2 antibodies as well as TAMRA fluorescence. As expected,
multiple immunopositive bands appear because the O-GlcNAc modification
occurs on numerous proteins throughout the cell. C) Representative immunoblot
show significantly augmented O-GlcNAc levels with AdOGT. D) Representative
TAMRA-GlcNAc gel showing augmented O-GlcNAc levels despite no change in
total glycoprotein levels (ProQ gel staining, n=3/group) with AdOGT *p<0.05 vs. 0
MOl AdOGT.
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To evaluate the effects of OGT overexpression on post-hypoxic cardiac
myocyte survival, similarly-treated cardiac myocytes were subjected to hypoxia
(three hours) and reoxygenation (one hour). Post-hypoxic media were harvested
and assayed for LDH release and cells were evaluated for PI positivity. A
significant (p < 0.05) decrease in post-hypoxic LDH release was seen with 100
Mal (67 ± 15% of 0 Mal) compared with 0 Mal AdOGT treated NRCMs (Figure
15A). Also, we observed a significant reduction in PI positivity at 100 Mal
(66 ± 7% of AdGFP) compared with AdGFP treated NRCMs (Figure 158).
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Figure 16. A) OGT overexpression improved post-hypoxic cardiac myocyte
survival. LDH release was spectrophotometricallY determined from the media
following hypoxia-reoxygenation (n=4-6/group). B) OGT overexpression
attenuated post-hypoxic injury according to propidium iodide staining. *p<0.05 vs.
o Mal AdOGT or 100 Mal AdGFP.
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C.2. OGT inhibition exacerbates post-hypoxic cardiac myocyte injury:
Loss-of-function for OGT was evaluated by incubating cultured NRCMs
(n = 6/group) with Vehicle (0.1 % DMSO) or OGT inhibitors (1.0 IJmol/L TT04 or
10 IJmollL TT40) for two hours prior to protein harvest and immunoblotting for 0GlcNAc levels. The concentrations of TT04 and TT40 used were not toxic to the
cells under normoxic conditions. Significant reductions (65 ± 7%, P < 0.05) in 0GlcNAc levels were observed with TT04 treatment compared to Vehicle (Figure
16A). We observed similar results with RL2, an additional O-GlcNAc antibody as
shown in bar graph (Figure 16A). A similar phenomenon was observed with a
related OGT inhibitor, TT40 (Figure 168). There was no significant difference in
glycoprotein levels following OGT inhibition (100 ± 8% of Vehicle, p = NS)
compared with Vehicle (100 ± 4%) according to Pro-Q Emerald staining (Figure
16C) demonstrating that the OGT inhibitor (TT04) does not alter other
glycosylation processes. As with virtually all known compounds, no absolute and
exclusive claims can be made regarding potential non-specific effects.
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Figure 17. Evaluation of effects of OGT inhibition on post-hypoxic cardiac
myocyte survival. NRCMs were treated with the OGT inhibitor, TT04 or TT40,
prior to protein harvest or H/R. A) Densitometric analysis and representative
immunoblots for O-GlcNAc levels following TT04 treatment show significant
reduction in O-GlcNAc levels. Multiple bands occur because O-GlcNAc is a posttranslational modification occurring on a plethora of intracellular proteins
(n=6/group). B) Densitometric analysis and representative immunoblots for 0GlcNAc levels following TT40 treatment show significant decrease in O-GlcNAc
levels (n=3/group). C) Densitometric analysis and representative ProQ emerald
stained gel for glycoprotein levels following TT04 treatment show no change in
glycoprotein levels (n=4/group).

To evaluate the effects of OGT inhibition on cardiac myocyte survival posthypoxia, cardiac myocytes (n = 6/group) were treated with TT04 , subjected to
hypoxia-reoxygenation, and media harvested to measure LDH release. Inhibition
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of OGT with TT04 (172 ± 18%, p<0.05) or TT40 (227±30%, p<0.05) significantly
augmented post-hypoxic LDH release compared to vehicle (Figure 17A).
Moreover, PI positivity was significantly more following OGT inhibition with TT04
(132 ± 10%, P < 0.05) compared to Vehicle (Figure 178).
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determined from the media following hypoxia-reoxygenation (n=6/group). B)
OGT inhibition via TT04 worsens post-hypoxic injury reflected by the significant
increase in PI positive cells (n=4/group). *p<0.05 vs. Vehicle.

C.3. Knockdown of OGT sensitizes cardiac myocytes to post-hypoxic
death: NRCMs (n

~

4/group) were treated with OGT siRNA or Control siRNA for

36 hours to knockdown OGT expression at the mRNA level. The transfection
efficiency for the siRNA was estimated to be greater than 90% (Figure 18A).
Whole cell Iysates immunoblotted for OGT and O-GlcNAc showed significant
reductions in OGT levels (49 ± 8% of Control, p < 0.05) and O-GlcNAc levels
(64 ± 5% of Control, p < 0.05) for OGT siRNA-treated NRCMs compared with
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control siRNA-treated NRCMs (Figure 188-C). There was no difference in

0-

tubulin levels between OGT siRNA- and Control siRNA-treated myocytes
according to western blot (Figure 188).
To investigate the effects of OGT gene knockdown on cardiac myocyte
survival post-hypoxia, cardiac myocytes (n=6/group) were treated with 30 nmol/L
OGT siRNA or Control siRNA for 36 hours, subjected to hypoxia-reoxygenation,
and media harvested to measure LOH release. There was a significant
(120 ± 2% of control p < 0.05) augmentation in post-hypoxic LOH release in OGT
siRNA-treated NRCMs compared to Control siRNA-treated NRCMs (Figure 180).
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Figure 19. Effects of OGT gene knockdown on post-hypoxic NRCM survival
(n=6/group). A) NRCMs transfected with fluorescently tagged control siRNA
showing a transfection efficiency of more than 90%. B) Knockdown of OGT
significantly reduces OGT protein levels according to immunoblotting in OGT
siRNA-treated compared with Control siRNA treated NRCMs. C) Whole cell
Iysates from OGT siRNA-treated NRCMs showed a significant decrease in 0GlcNAc levels compared with those from Control siRNA-treated NRCMs
according to western blotting. D) NRCMs treated with OGT siRNA were more
sensitive to hypoxia-induced injury (according to LDH release) compared with
NRCMs treated with Control siRNA. *p< 0.05 vs. Control siRNA.
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C.4. Deletion of OGT gene sensitizes cardiac myocytes to hypoxic injury:
Neonatal mouse cardiac myocytes (NMCMs, n=3/group) carrying only 10xPflanked copies of the OGT gene (Figure 19A) were infected with adenovirus
expressing

CRE-recombinase

for

72 hours.

Whole

cell

Iysates

were

immunoblotted for CRE-recombinase, OGT, and O-GlcNAc modification. NMCMs
expressing CRE-recombinase (Figure 19B) showed significant reductions in OGT
(44 ± 16% of control, Figure 19C) and O-GlcNAc levels (28 ± 5% of control,
Figure 190). To assess the effect of OGT deletion on cardiac myocyte survival
following hypoxia, 72 hour post-AdCRE infection, NMCMs were subjected to 3 h
of hypoxia and 1 h of reoxygenation and media harvested for LOH assay. A
significant (p < 0.05) elevation in LOH release was observed at 50 MOl
(122 ± 12% of control) compared with 0 MOl AdCRE (Figure 19E).
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Figure 20. Effects of OGT deletion on survival following hypoxia in cardiac
myocytes. NMCMs were infected with AdCRE 72 hours prior to protein harvest
or H/R. A) Representative genotyping PCR results showing 10xP-fianked or WT
OGT gene. B) Cardiac myocytes from homozygous litters were exposed to
AdCRE or no virus. There was a significant (p<0.05) increase in CRErecombinase expression (n=4/group) and C) a significant (p<0.05) decrease in
OGT levels with 50 MOl compared with 0 MOl AdCRE (n=4/group). D) O-GlcNAc
levels were markedly decreased at 50 MOl compared with 0 MOl AdCRE
(n=4/group). E) LDH release was significantly (p<0.05) elevated at 50 MOl
compared with 0 MOl AdCRE following hypoxia-reoxygenation (n=4/group).
*p<0.05 vs. 0 MOl AdCRE.

86

D. ROLE OF GCA IN HYPOXIA-INDUCED CARDIAC MYOCYTE INJURY
D.1. GCA (AdGCA) overexpression exacerbates post-hypoxic cardiac
myocyte death: Forty-eight hours following AdGCA infection of isolated NRCMs
(n>/=5 per group), total cellular proteins were isolated for GCA protein and 0GlcNAc levels (via western blot analysis). Adenoviral overexpression of GCA
significantly (p<0.05) augmented GCA protein levels (Figure 20A). Such
elevation corresponded with a significant (p<0.05) reduction in O-GlcNAc levels
(48±7% of 0 Mal AdGCA) (Figure 208). Similar findings were seen with another
O-GlcNAc antibody, RL2 (65±8% of 0 Mal AdGCA; Figure 208). Immunoblots for
O-GlcNAc levels show multiple immunopositive bands because O-GlcNAc is a
posttranslational modification, not a single protein (Figure 208). Other studies
have demonstrated similar findings in various cell lines (333) and NRCMs(33,
34). Equal protein loading was confirmed by densitometric analysis of Ponceaustained membranes.
To evaluate the effects of GCA overexpression on post-hypoxic cardiac
myocyte survival, similarly treated cardiac myocytes were subjected to hypoxia (3
h) and reoxygenation (1 or 6 h). Post-hypoxic media was harvested for LDH
release, and additional post-hypoxic NRCMs were stained with PI to assess cell
death. Myocytes infected with AdGCA were more sensitive to hypoxia-induced
injury by the first hour of reoxygenation according to LDH release (150±23% of 0
Mal AdGCA, p<0.05; Figure 20C). To determine whether the detrimental effect
of AdGCA on post-hypoxic cardiac myocytes was short-lived, similarly treated
NRCMs were reoxygenated for 6 hours after 3 hours of hypoxia. The longer
87

duration of reoxygenation (6 hours) still showed exacerbated cellular injury in
AdGCA NRCMs, according to LOH release (179±14% versus 136±8% for
AdGFP, p<0.05; Figure 20C). Another index of cell death i.e. PI positivity
confirmed our one hour (17±2% versus 10±1% for AdGFP; Figure 200) and six
hour (34±3% versus 24±2% for AdGFP, p<0.05; Figure 200) post-post-hypoxic
LOH data compared to 0 MOl AdGCA or AdGFP.
Cell damage was not significantly different among AdGCA, AdGFP, or
uninfected NRCMs under normoxia according to LOH release (109±3% of control
versus 93±3% of control, p>0.05) and PI positivity (14±1% for GCA versus
13±1 % for AdGFP versus 12±1 % for control, p>0.05). Such results confirm that
viral infection does not affect cell survival or O-GlcNAc levels in this system.
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Figure 21. Myocytes were infected with AdGFP or AdGCA (0 or 100 Mal) 48
hours before protein isolation or hypoxia/reoxygenation. A) Bar graph of real
time PCR showing significantly augmented GCA mRNA levels at 100 Mal
compared to 0 Mal AdGCA (n=3/group). B) Representative immunoblot of GCA
protein shows significant elevation in GCA levels following AdGCA infection. C)
Densitometric analysis and representative immunoblot of O-GlcNAc levels.
AdGCA significantly reduced O-GlcNAc levels. As expected, multiple
immunopositive bands appear because the O-GlcNAc modification occurs on
numerous proteins throughout the cell (n=5/group). D) GCA overexpression
exacerbated post-hypoxic cardiac myocyte damage according to LDH release
(n=5/group). E) GCA overexpression aggravated post-hypoxic injury according
to propidium iodide positivity (n=4-5 /group). *P<0.05 vs. 0 Mal AdGCA or 100
Mal AdGFP.

89

0.2. GCA inhibition attenuates post-hypoxic cardiac myocyte injury:
NRCMs (n=61 group) were treated with PUGNAc (GCA inhibitor) overnight before
protein harvest, then immunoblotted for a-GlcNAc levels. PUGNAc significantly
increased a-GlcNAc levels (878±215% of control, p<0.05) compared to vehicle
(Figure 21A).
Additional NRCMs (n=61 group) were treated with PUGNAc, subjected to
hypoxia/reoxygenation, and media harvested to measure LDH release. Inhibition
of GCA (with PUGNAc) (70±10% of Vehicle, p<0.05; Figure 218) significantly
attenuated post-hypoxic LDH release at the end of the first hour of
reoxygenation. The protective effect of augmented a-GlcNAc levels (with
PUGNAc) was still seen at 6 hours of reoxygenation according to LDH release
(133±11% for PUGNAc, p<0.05 versus 177±14% for Vehicle; Figure 218).
Similar protective effects were observed using PI positivity as another index of
cell death at both one (9±1 % versus 13±1 % for vehicle, p<0.05; Figure 21 C) and
six hour (21±2% versus 36±2% of Vehicle, p<0.05; Figure 21C) reoxygenation
time points. PI positivity and PI positivity. PUGNAc or Vehicle treatment did not
significantly alter normoxic/aerobic cellular viability compared with untreated
NRCMs under normoxia according to LDH release (p>0.05, 90±8% of control
versus 104±8% of Control) and PI positivity (p>0.05, 12±1 % for PUGNAc versus
13±1 % for Vehicle versus 13±1 % for Control).
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Figure 22. NRCMs were subjected to pharmacological repression of GCA
activity (n=6/group). A) Densitometric analyses of O-GlcNAc Western blots show
significantly elevated O-GlcNAc levels compared to Vehicle. Representative
immunoblots for O-GlcNAc levels following PUGNAc treatment show a significant
increase in O-GlcNAc levels compared to Vehicle. Multiple bands occur because
O-GlcNAc is a posttranslational modification. B) GCA inhibition with PUGNAc
diminished post-hypoxic injury in NRCMs (according to LDH release) compared
with Vehicle. C) GCA inhibition with PUGNAc reduced post-hypoxic injury (per
PI positivity) compared with Vehicle. *P<O.05 vs. Vehicle.
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0.3. Knockdown of GCA reduces post-hypoxic cardiac myocyte injury:
NRCMs (n=6/group) were treated with 60 nmol/L GCA siRNA or Control siRNA
for 72 h to knockdown GCA expression. GCA knockdown significantly (p<0.05)
reduced GCA protein levels compared to Control siRNA, despite no change in atubulin levels (Figure 22A). GCA siRNA significantly (p<0.05) augmented 0GlcNAc levels (132±12% of Control, P<0.05) compared to Control siRNA (Figure
22A & 8).
Additional NRCMs were treated with GCA or Control siRNA, subjected to
hypoxia/reoxygenation, and media harvested to measure LOH release. GCA
siRNA significantly (p<0.05) reduced post-hypoxic LOH release after 1 h
(72±10% of Control siRNA; Figure 22C) and 6 hours (130±4% for GCA siRNA
versus 170±26% for Control siRNA; Figure 22C) of reoxygenation compared to
Control siRNA. In addition, GCA siRNA significantly diminished PI positivity at 6
hours (22±2% for GCA siRNA versus 33±2% for Control siRNA, p<0.05; Figure
220) compared with Control siRNA. GCA (102±5%) or Control siRNA (97±5%)
treatment did not cause significant cell damage compared with untreated NRCMs
under normoxialaerobic conditions.
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Figure 23. A) GCA message knockdown (siRNA) significantly reduced GCA
protein levels compared with Control siRNA (n=5-6/group). B) Densitometric
analysis of O-GlcNAc immunoblots showed a significant increase in O-GlcNAc
levels for GCA siRNA compared with Control siRNA. Representative immunoblot
for Iysates from GCA siRNA-treated NRCMs showing augmented O-GlcNAc
levels compared to Control siRNA. C) GCA siRNA-treated NRCMs were more
resistant to hypoxia-induced injury according to LDH release and D) PI positivity
compared to Control siRNA. *P<O .05 vs. Control siRNA.
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E. ROLE OF

O~GlcNAc

IN ER

STRESS~INDUCED

CARDIOMYOCYTE DEATH

E.1. Hypoxia induces ER stress: ER stress markers were evaluated to confirm
that hypoxia induces ER stress. Cardiac myocytes subjected to six hours of
hypoxia and six hours of reoxygenation then immunoblotted for ER stress
proteins showed significantly (p<0.05) augmented UPR-inducible proteins, Grp
94 (169+/-14% of Normoxia), Grp 78 (136+/-16% of Normoxia), and calreticulin
(135+/-15% of Normoxia) as shown in Figure 23A and B. Moreover, hypoxia
induced apoptosis according to significant (p<0.05) PARP cleavage (50+/-16% of
normoxia) despite no change in o-tubulin protein levels (Figure 23A & B). These
results indicate that hypoxia induces ER stress in cultured neonatal cardiac
myocytes and confirms previous findings by other groups (283, 293). Because
hypoxia/ischemia exact multiple insults on cardiac myocytes, we wanted to
isolate one such pathology (ER stress) and ask whether O-GlcNAc signaling
could interfere with this specific pro-death pathway.
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Figure 24. Cardiac myocytes (n=6/group) were subjected to hypoxiareoxygenation and activation of ER stress evaluated. A) Hypoxia activated ER
stress as reflected by immunoblots showing augmented Grp 94, Grp 78, and
calreticulin levels. B) Densitometric quantification of immunoblots showed
significant post-hypoxic upregulation of Grp 94, Grp 78, Calreticulin (Cal), and
PARP cleavage (expressed as cleaved/uncleaved PARP in bar graph). * p<O.05
vs. Normoxia.

E.2. Genetic manipulation of O-GlcNAc signaling alters maladaptive ER
stress signaling: As shown above and supported by other groups, augmented
O-GlcNAc levels attenuate post-hypoxic cardiac myocyte death (33, 34), postischemic contractile dysfunction in isolated perfused hearts (189-191), and
hemorrhagic shock-mediated inflammation (337, 338).

Because numerous

studies have implicated ER stress in the pathogenesis of post-ischemia/hypoxic
injury(249, 283, 293), we evaluated whether genetic manipulation of O-GlcNAc
signaling affects ER stress-induced cardiac myocyte death, per se, under
normoxic conditions.
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Cardiac myocytes infected with replication deficient adenovirus carrying
GFP, OGT, or GCA gene for 24 hours, were treated with prototypical ER stress
inducers, Tunicamycin (TM)(72) or Brefeldin A (BfA)(250), for 24 hours.

0-

GlcNAc levels and the levels of several UPR inducible proteins were assessed
by immunoblotting.

BfA treatment significantly (p<0.05) augmented O-GlcNAc

levels (206±19% of AdGFP, Figure 24A).

OGT overexpression significantly

(296±32% for AdOGT + BfA vs. 206 ±19% for AdGFP + BfA, p<0.05) increased
O-GlcNAc levels over the levels already induced by ER stress (Figure 24A).
Although induction of ER stress in GCA overexpressed cells augmented 0GlcNAc levels, it was still less than baseline O-GlcNAc levels (Figure 24A).
Similar changes in O-GlcNAc signaling were observed following induction of ER
stress with TM (Figure 24B).
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Figure 25_ Normoxic cardiac myocytes (n=6/group) were treated with AdGFP,
AdOGT, or AdGCA, subjected to ER stress with Brefeldin A (BfA, inhibit ER-golgi
protin transport) or Tunicamycin (TM, inhibits N-glycosylation). Whole ceillysates
was immunoblotted for O-GlcNAc and a-tubulin . A) BfA treatment augmented 0GlcNAc levels. OGT overexpression significantly augmented O-GlcNAc levels
over that induced by BfA as shown in immunoblot and densitometric
quantification of immunoblots. B) TM treatment augmented O-GlcNAc levels.
OGT overexpression significantly augmented O-GlcNAc levels over that induced
by TM. n=6/group. * p<O.05 vs. AdGFP, ** p<O.05 vs. AGFP + BfA or AdGFP +
TM.
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BfA-induced ER stress stimulated significant (p<O.OS) increase in ER
chaperones, Grp 94 (18S±14% AdGFP), Grp 78 (491±S6% AdGFP), and
Calreticulin (1SS±34% AdGFP) as shown in Figure 2SA & B. Moreover, BfA
treatment activated the maladaptive arm of ER stress response according to
PARP cleavage (231±29% AdGFP) and CHOP activation (839±29% AdGFP) as
shown in Figure 2SA & B. OGT overexpression significantly reduced BfAmediated ER stress reflected by reduced Grp 94 (144±10% for AdOGT + BfA vs.
18S±14% for AdGFP + BfA) and Grp 78 (303±28% for AdOGT + BfA vs.
491 ±S6% for AdGFP + BfA) protein levels (Figure 2SA & B). Furthermore, OGT
overexpression significantly (p<O.OS) attenuated BfA-induced activation of
maladaptive ER stress response according to diminished CHOP activation
(400±77% for AdOGT + BfA vs. 839±29% for AdGFP + BfA, Figure 2SA & B).
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Figure 26. Normoxic cardiac myocytes (n=6/group) were treated with AdGFP,
AdOGT or AdGCA, subjected to ER stress with BfA and whole cell Iysates
immunoblotted for Grp 94, Grp 78, Calreticulin, PARP and CHOP. A) Total
protein was isolated from selected cultures and immunoblotted for ER stress
indicators. OGT overexpression significantly attenuated, while GCA
overexpression did not change BfA-induced ER stress according to
immunoblotting. B) Densitometric quantification of immunoblots showed
significant reduction in BfA-induced increase in Grp 94, Grp 78, and CHOP levels
with OGT overexpression. OGT overexpression did not affect Calreticulin
expression or PARP cleavage (expressed as cleaved PARP/uncleaved PARP).
GCA overexpression did not significantly change BfA-induced Grp94, grp78,
Calreticulin, PARP cleavage and CHOP levels. * p<O.05 vs. AdGFP, ** p<O.05
vs. AGFP + BfA.
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To confirm the protective effects of augmented O-GlcNAc levels (via OGT
overexpression) on the activation of maladaptive unfolded protein response, we
examined

whether OGT overexpression

affects

ER

stress

induced

by

Tunicamycin (TM), an inhibitor of N-glycosylation of nascent ER proteins. OGT
overexpression significantly (p<O.05) reduced the TM-induced ER stress
according to Grp 94 (320±33% for AdOGT + TM vs. 421±18% for AdGFP + TM),
Grp 78 (322±47% for AdOGT + TM vs. 536±31% for AdGFP + TM), and CHOP
activation (1549±239% for AdOGT + TM vs. 3065±585% for AdGFP + TM) as
shown in Figures 26A & B. In both BfA and TM treatments, OGT overexpression
did not affect ER stress-mediated increase in calreticulin protein level or PARP
cleavage (Figure 26A-B). GCA overexpression did not alter BfA or TM-mediated
increases in the ER chaperones: Grp94, Grp78 and calreticulin (Figure 26A-B).
Finally, AdGCA did not affect ER stress mediated apoptosis according to CHOP
activation and PARP cleavage (Figures 25 and 26). These results demonstrate
that known ER stress inducers (BfA and TM) augment protein levels of three
well-characterized UPR-inducible proteins in cardiomyocytes, consistent with
other groups(283, 293}.
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Figure 28. Normoxic cardiac myocytes (n=6/group) were treated with AdGFP,
AdOGT, or AdGCA, subjected to ER stress with TM and whole cell Iysates
immunoblotted for O-GlcNAc, Grp 94, Grp 78, Calreticulin, PARP and CHOP. A)
OGT overexpression significantly mitigated, while GCA overexpression did not
change TM-induced ER stress according to immunoblotting. B) Densitometric
quantification of immunoblots showed significant reduction in TM-induction of Grp
94, Grp 78, and CHOP with OGT overexpression despite no change with GCA
overexpression. * p<O.05 vs. AdGFP, ** p<O.05 vs. AdGFP + TM.
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E.3. Genetic manipulation of Q-GlcNAc signaling affects ER stressmediated cardiac myocyte death: During prolonged or severe ER stress, the
cell death pathways can be activated. Therefore, we questioned whether genetic
manipulation of the two enzymes involved with O-GlcNAc signaling affects ER
stress-induced cardiac myocyte death. In the absence of ER stress, neither OGT
overexpression nor GCA overexpression altered cellular viability according to PI
positivity (Figure 27A). OGT overexpression significantly (38±3% for AdOGT +
BfA vs. 47±3% for AdGFP + BfA, p<O.05) attenuated, while GCA overexpression
exacerbated (60±2% for AdGCA + BfA, p<O.05) BfA-induced cell death according
to PI positivity (Figure 27A). Neither OGT nor GCA overexpression significantly
altered BfA mediated cardiomyocyte apoptosis according to Caspase 3/7 activity
(Figure 27B).
Similarly,

OGT

overexpression

significantly

mitigated

TM-induced

cardiomyocyte death (21±3% for AdOGT + TM vs. 34±3% for AdGFP + TM,
p<O.05,

Figure 27C).

cardiomyocyte

death

GCA overexpression did not alter TM-mediated
(Figure

27C).

Moreover,

both

OGT

and

GCA

overexpression did not significantly alter TM-mediated cardiomyocyte apoptosis
according to Caspase 3/7 activity (Figure 270). Taken together, these results
indicate that augmented O-GlcNAc levels are protective against ER stressinduced cell death.
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Figure 28. Normoxic cardiac myocytes ((n=6/group) were treated with AdGFP,
AdOGT or AdGCA, subjected to ER stress with BfA and cell death evaluated
using the nuclear stain, PI or measuring caspase activity. A) OGT
overexpression significantly attenuated, while GCA overexpression exacerbated
ER stress-induced cardiac myocyte death according to PI positivity. B) OGT or
GCA overexpression did not change ER stress-induced cardiomyocyte
apoptosis. C) OGT overexpression also significantly reduced TM-induced cardiac
myocyte death despite no change with GCA overexpression according to PI
positivity. D) Neither OGT nor GCA overexpression affected TM-induced
cardiomyocyte apoptosis. n>/=5/group. * p<O.05 vs. AdGFP, ** p<O.05 vs.
AdGFP + BfA or TM.
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E.4. Q-GlcNAcase inhibition reduces pro-death UPR signaling: Next, we
used a complementary approach to elevate O-GlcNAc levels by inhibiting 0GlcNAcase with PUGNAc(111). Cardiac myocytes were treated with PUGNAc or
Vehicle (0.1 % ethanol) three hours prior to ER stress induction (with TM or BfA,
24 hours) and whole cell Iysates immunoblotted for O-GlcNAc levels and ER
stress indicators. Inhibition of O-GlcNAcase significantly augmented O-GlcNAc
levels above that induced by BfA (Figure 28A) or TM (Figure 28B) alone.
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Figure 29. Normoxic cardiac myocytes were treated with either Vehicle or 0GlcNAcase inhibitor (PUGNAc) and subjected to ER stress (with BfA or TM). A)
Western blots of whole cell Iysates showed augmented O-GlcNAc levels with 0GlcNAcase inhibition compared to Vehicle. O-GlcNAcase inhibition augmented
O-GlcNAc levels above that induced by BfA. B) O-GlcNAcase inhibition
significantly increased O-GlcNAc levels above that induced by TM. n=4/group.
*p<0.05 vs. Vehicle, ** p<0.05 vs. BfA or TM.
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L

Moreover, O-GlcNAcase inhibition significantly (p<O.OS) reduced BfA-induced ER
stress according to Grp 94 (124±12% for PUGNAc + BfA vs. 179±18% for BfA
alone), Grp 78 (136±7% for PUGNAc + BfA vs. 224±S1% for BfA alone), and
calreticulin (148±26% PUGNAc + BfA vs. 268±6% for BfA alone) shown in Figure
29.

Additionally, O-GlcNAcase inhibition significantly (p<O.OS) blocked the

activation of maladaptive ER stress response as reflected by diminished CHOP
activation (S79±76% for BfA + PUGNAc vs. 1474±216% for BfA alone, Figure
29). Similar findings were observed with TM. PUGNAc treatment significantly
attenuated TM-induced ER stress according to Grp 94 (171 ±3% for PUGNAc +
TM vs. 28S±73% for TM alone, p<O.OS), Grp 78 (164±12% for PUGNAc + TM vs.
293±40% for TM alone, p<O.OS), Calreticulin (174±1S% PUGNAc + TM vs.
260±49% for TM alone, p<O.OS) as represented in Figure 30.

Finally, 0-

GlcNAcase inhibition reduced TM-induced CHOP activation, but did not affect
BfA or TM induced PARP cleavage (Figure 30).

105

A)
+

Vehicle

+
+

PUGNAc

+

Brefeldin A
Grp94
Grp78
Calreticulin
Uncleaved PARP

•

..
•
•
.
.. II

III

.

Cleaved PARP
CHOP

+

94
72
55
116
62

•

I•

25

a-tubulin

50

B.

CHOP
2000

*

1750

PARP
Grp 78 Calreticulin

Vehicle
Brefeldin A

PUGNAc

+ +

-

+ +
+

+ + - + +
- +

+ +

-

- + +

-

- +

+ + - + +

+

+ + - + +
-

- +

Figure 30. Normoxic cardiac myocytes ((n=5-6/group) were pre-treated with
either Vehicle or O-GlcNAcase inhibitor (PUGNAc) and subjected to ER stress
with BfA. A) Western blots of whole cell Iysates showed significant reduction in
BfA-mediated activation of Grp 94, Grp 78 , Calreticul in and CHOP protein levels
with O-GlcNAcase inhibition. B) Densitometric quantification of immunoblots
showed significantly reduced Grp 94, Grp 78, Calreticulin, and CHOP protein
levels with O-GlcNAcase inhibition. PUGNAc treatment did not affect BfAmediated PARP cleavage (expressed as cleaved PARP/uncieaved PARP). *
p<O.05 vs. Control , ** p<O.05 vs. BfA.
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Figure 31. Normoxic cardiac myocytes (n=5-6/group) were pre-treated with
either Vehicle or O-GlcNAcase inhibitor (PUGNAc) and subjected to ER stress
with TM. Whole ceillysates were immunoblotted for ER chaperones (Grp 94, Grp
78 and Calreticulin) and pro-apoptotic (CHOP and PARP) proteins. A) 0GlcNAcase inhibition showed significant reduction in BfA-mediated activation of
Grp 94, Grp 78, Calreticulin and protein levels. Moreover, GCA inhibition
significantly reduced the TM mediated increase in CHOP protein levels despite
no effect on PARP cleavage compared to TM alone according to representative
immunoblots and B) densitometric quantification. * p<O.05 vs. Control, ** p<O.05
vs .TM.
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E.4. Q·GlcNAcase inhibition mitigates ER stress·induced cardiac myocyte
death: Like OGT overexpression, O-GlcNAcase inhibition (with PUGNAc) has
been shown to be cytoprotective during hypoxia, ischemia and oxidative
stress(190). Here, O-GlcNAcase inhibition with PUGNAc significantly attenuated
BfA-induced cardiomyocyte death (1B±7% for PUGNAc + BfA vs. 41±7% for BfA
alone, p<O.OS, Figure 31A). Such results were further supported by significantly
attenuated TM-induced ER stress with O-GlcNAcase inhibition with PUGNAc
(1S±3% PUGNAc + TM vs. 33±6% for TM alone, p<O.OS, Figure 31B). Thus,
shifting the cellular balance in favor of O-GlcNAcylation via genetic or
pharmacologic means mitigates ER stress-induced cell death.

Inhibition of 0-

GlcNAcase did not significantly alter BfA or TM-induced apoptosis according to
Caspase 3/7 activity (Figure 31 C and D).
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F. PROTEIN MODIFICATION BY O-GlcNAc
Numerous studies have documented an ever-growing list of proteins modified by
O-GlcNAc. However, sparse information exists on specific cardiac proteins
modified by O-GlcNAc. According to the immunoblotting data in Figures above, it
appears that several proteins are modified by O-GlcNAc in cardiac myocytes. In
Figure 32, we attempted to specifically identify some of these as potential
candidates for cardioprotection. Proteins isolated from cultured cardiac myocytes
treated with vehicle or PUGNAc were harvested as described above.

Two-

dimensional gel electrophoresis revealed at least 13 spots on which the 0GlcNAc modification (as evidenced by CTD antibody positivity) was augmented
after PUGNAc treatment (Figure 32A). Analysis of these 13 spots (Table 4) by
Matrix Assisted Laser Desorption Iionization- Time Of Flight (MALDI-TOF) mass
spectrometry revealed several proteins involved in metabolism and one (VDAC)
that piqued our interest because of its participation in the mitochondrial
permeability transition pore (mPTP). Next, we performed an immunoprecipitation
experiments to confirm that VDAC was modified by pulling down the O-GlcNAcmodified proteins and performing an immunoblot against VDAC.

Indeed, the

band corresponding to ==30 kDa was also augmented in the PUGNAc sample
compared with vehicle (Figure 328).
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Table 4: List of MALOI-TOF protein 10
Spot
No.

Protein
Identity

Accession
No.

Molecular
Weight,
Oa

Isoelectric
Point

Sequence
Coverage,
%

1

HSP60

CAA38564

60965

6.1

32

2

HSP60

CAA38564

60965

6.1

39

3

Desmin

P48675

53325

5.3

39

4

-Actin

Q61264

37729

5.4

24

5

HSP27

NP 114176

22865

6.1

28

6

VOAC

AAH60558

32060

8.4

54

7

Malate
dehydrogenase

AAH63165

36117

8.9

35

8

Malate
dehydrogenase

P04636

35655

9.1

34

9

Glyceraldehyde
3-phosphate
dehyd rogenase

P04797

35705

8.6

28

10

Glyceraldehyde
3-phosphate
dehydrogenase

P04797

35705

8.6

27

11

Fructosebisphosphate
aldolase

NP 036627

39220

8.5

40

12

Fructosebisphosphate
aldolase

NP 036627

39220

8.5

28

13

Pyruvate kinase

P11980

57649

7.6

21
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Figure 33. Cardiomyocytes were treated with Vehicle or PUGNAc, whole cell
lysate isolated and O-GlcNAc-modified proteins identified via two-dimensional
immunoblotting and MALDI-TOF. A) 2D immunoblotting for O-GlcNAc identified
several proteins with enhanced immunoreactivity, which was subsequently
submitted for mass spectrometry analysis via para"el silver-stained gels. Several
proteins displayed augmented O-GlcNAc modification after PUGNAc treatment,
including VDAC (spot 6); n=2. See the Table 4 for protein identities. pi indicates
isoelectric point. B) Additional samples separated on narrower isoelectric point
and molecular weight ranges to enhance the ability to identify the VDAC spot. C)
Additional protein isolates were subjected to immunoprecipitation (IP) with an
antibody against O-GlcNAc, then immunoblotted (18) for VDAC.
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F.1. VDAC is a mitochondrial target of O-GlcNAc: Our focus on VDAC is
based on its identity as a putative element in formation of the mPTP, which
represents a significant and proximal event in the commitment to cell death.
Although this serves only as an initial foray into the likely numerous proteomic
changes associated with O-GlcNAc in this system, this singular finding is
intriguing and consistent with the in vitro evidence for O-GlcNAc-mediated
cardioprotection. It is important to note that lower-molecular-weight proteins are
not shown in the 1-dimensional gels earlier in this study because the Western
blots were not optimized for lower-molecular-weight ranges.

Nevertheless, the

appearance of the lower-molecular-weight bands appeared after the saturation of
some of the higher-molecular-weight bands (by which time the exposure was
stopped for the analyses shown in the earlier Figures).
Because our MALDI-TOF data identified VDAC as a target of O-GlcNAc
modification, we assessed O-GlcNAc-modified VDAC levels following inhibition
OGT (with TT04) or GCA (via PUGNAc) as a possible mechanistic link between
O-GlcNAc signaling and the mitochondria. Adult wild-type mice were treated with
TT04 (10mg/kg), PUGNAc (50 mg/kg IP) or isovolumic Vehicle (0.1 % DMSO or
0.1 % Ethanol) intraperitoneally, and cardiac mitochondrial proteins were
evaluated to ascertain whether such changes in VDAC modification suggested
by the 2-dimensional gels (Figure 32) also occurred in the adult myocardium.
Fractionation of hearts from Vehicle-, TT04- and PUGNAc-treated mice yielded
clean, largely intact mitochondria (Figure 33A).

Further examination of the

mitochondrial fraction revealed that cardiac mitochondria from TT04-treated mice
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contained reduced O-GlcNAc-modified-VOAC compared with those from Vehicletreated mice (Figure 338). Moreover, an immune-independent technique further
confirmed the co-IP findings showing reduction in O-GlcNAc modification of
VOAC with OGT inhibition (Figure 33C). Conversely, more VOAC was O-GlcNAc
modified after PUGNAc treatment compared with Vehicle and such change
occurred without a difference in total VOAC according to immunoblotting (Figure
330). Again, VOAC is not the only O-GlcNAc modified protein.
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Figure 34. Adult mice were treated with vehicle (V; n=4), TT04 (n=4) or
PUGNAc (P; n=4), and cardiac mitochondria were isolated. A) Total protein was
isolated from mitochondrial and non-mitochondrial aliquots. Immoblotting for
cytochrome c oxidase subunit 4 (COX IV) and a-tubulin in the mitochondrial nonmitochondrial Iysates confirmed sound mitochondrial isolation. B) OGT inhibition
(via TT04) reduced O-GlcNAc levels on at least one mitochondrial protein
(VDAC). Co-immunoprecipitation for O-GlcNAc-modified-VDAC showed a
reduction in O-GlcNAc-modified-VDAC in adult cardiac mitochondria from TT04treated mice compared with Vehicle-treated mice, despite no difference in total
VDAC levels from both groups (n = 4/group). C) GCA inhibition (via PUGNAc)
augmented O-GlcNAc levels on at least one mitochondrial protein (VDAC). Coimmunoprecipitation for O-GlcNAc-modified-VDAC showed an increase in 0GlcNAc-modified-VDAC in adult cardiac mitochondria from PUGNAc-treated
mice compared with Vehicle-treated mice, despite no difference in total VDAC
levels from both groups (n = 4/group). D) Immunoprecipitation for VDAC and
enzymatic labeling of O-GlcNAc-modified proteins confirmed the reduction in 0GlcNAc-modified-VDAC in cardiac mitochondria from TT04-treated compared
with Vehicle-treated mice. There was no difference in protein loading according
to SYPRO ruby staining. *p < 0.05 vs. Vehicle .
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F.2. Effects of manipulation of O-GlcNAc levels on expression of mPTP
components: To determine if baseline manipulation of O-GlcNAc levels altered
the protein levels of mPTP components, whole cell Iysates from normoxic
NRCMs treated with AdGFP, AdGCA, Vehicle, PUGNAc, Control siRNA or GCA
siRNA were immunoblotted for CyP 0, ANT and VDAC. Neither augmented 0GlcNAc levels (PUGNAc or GCA siRNA) nor diminished O-GlcNAc levels
(AdGCA) significantly (p>O.05) changed CyP 0, ANT and VDAC protein levels
(Figure 34).
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Figure 35. Expression of putative molecular components of mitochondrial
permeability transition pore (mPTP). Expression of CypD, ANT, and VDAC were
not significantly affected by A) genetic overexpression (n=4/group), B)
pharmacological inhibition (n=4/group), or C) siRNA knockdown of GCA
according to western blotting (n=4/group). P=NS for all comparisons.
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G.

O-GlcNAc MODIFICATION AND MITOCHONDRIAL-MEDIATED DEATH

PATHWAY
G.1. Effects of altered O-GlcNAc levels on hypoxia-induced Ca 2+ overload
G.1.i. Effects of OGT overexpression on hypoxia-induced Ca 2+ overload:
Several studies have implicated Ca 2 + overload as a key contributor to
mitochondrial permeability transition leading to ischemia-reperfusion injury and
interventions that reduce or delay the rise in [Ca 2+] block or delay myocardial
death (219, 244, 276, 277). In addition, inhibiting the rise in mitochondrial [Ca 2+]
has been shown to confer cardioprotection following acute MI or IRI (94, 218).
Moreover, dysregulation of mitochondrial Ca 2 + is known to induce mPTP
formation (63, 141).

Accordingly, we assessed whether OGT overexpression

affects Ca 2 + overload following hypoxia in NRCMs. OGT overexpression did not
alter baseline mitochondrial Ca 2 + levels but Significantly attenuated hypoxiainduced

mitochondrial

Ca 2 +

overload

(n=5/group, Figure 35).
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Figure 36. Evaluation of calcium overload in post-hypoxic cardiac myocytes
using Rhod-2AM (n=5/group). Myocytes were treated with AdNull or AdOGT.
Following hypoxia, myocytes undergo progressive calcium overload. Genetic
overexpression of OGT attenuates post-hypoxic calcium overload according A)
representative montage B) reoxygenation time-lapse graph and C) bar graph
representation of the change in rhod-2 fluorescence.
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G.1.ii. Effects of GCA manipulation on hypoxia-mediated Ca2 + overload: To
determine if manipulation of GCA levels affects hypoxia-induced Ca 2+ overload,
cardiac myocytes were treated with either AdGFP (48 hours, 100 MOls), AdGCA
(48 hours, 100 Mal), Vehicle (overnight), or PUGNAc (overnight, 200
loaded with the mitochondrial calcium indicator rhod-2 (2

~mol/L)

~mol/L),

and subjected

to three hours of hypoxia and one of reoxygenation. Time-lapse fluorescence
microscopy was initiated at the beginning of reoxygenation for changes in
mitochondrial Ca 2 + levels.

Augmentation of Ca 2+ levels is reflected by an

increase in rhod-2 fluorescence. Hypoxia sensitized myocytes to Ca 2+ overload.
GCA overexpression (AdGCA) exacerbated hypoxia-induced calcium overload
during reoxygenation reflected by a significant increase in rhod-2 fluorescence
(Figure 36A-8), whereas GCA inhibition (PUGNAc) attenuated hypoxia-induced
calcium overload compared to Vehicle (Figure 36A & C).
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Figure 37. Assessment of calcium overload in post-hypoxic cardiac myocytes
using Rhod-2AM (n>/=4/ group). Myocytes were treated with AdGFP or AdGCA
(A and B) or vehicle or PUGNAc (A ·and C). Following hypoxia, myocytes
undergo progressive calcium overload. Genetic overexpression of GCA
exaggerates, whereas pharmacological inhibition of GCA attenuates, posthypoxic calcium overload. *P<O.05 vs. AdGFP or Vehicle.
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G.2. Effects of altered O-GlcNAc levels on hypoxia-induced ROS generation
G.2.i. Effects of OGT overexpression on hypoxia-induced ROS production:
Reactive oxygen species (ROS) are important contributors to ischemiareperfusion injury. In fact, studies have shown that addition of antioxidants or
ROS scavengers delay the onset or attenuate ischemia-reperfusion injury (7,43,
168). Therefore, I evaluated the effects of overexpressing OGT to augment 0GlcNAc levels on hypoxia-induced ROS generation. NRCMs infected with 100
MOl of AdNull or AdOGT for 48h were loaded with DCF (2 IJmol/L) and subjected
to hypoxia for three hours. Time-lapse fluorescence microscopy was initiated at
the beginning of reoxygenation for changes in ROS levels. Augmentation of ROS
levels is reflected by an increase in DCF fluorescence.
myocytes

ROS generation which was

Hypoxia augmented

significantly attenuated

by OGT

overexpression. OGT ovexpression did not change baseline ROS levels (Figure
37).
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Figure 38. Evaluation of post-hypoxic ROS production in NRCMs treated with
AdNull or AdOGT using DCF (n=4 per group). Subjecting myocytes to hypoxia
augmented ROS production. An effect attenuated by genetic overexpression of
OGT. A) Representative montage showing DCF fluorescence. B) Quantitative
changes in mean DCF fluorescence (expressed as %) in NRCMs using timelapse fluorescent microscopy. C) Bar graph showing the change in DCF
fluorescent intensity between 1 minute and 61 minutes. *P<O.05 vs. AdNu11.
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G.2.ii. Effects of GCA manipulation on

hypoxia~mediated

ROS production:

To determine the effect of GCA manipulation on post-hypoxic ROS generation,
NRCMs treated with AdGFP, AdGCA, Vehicle or PUGNAc, were loaded with
DCF, and then subjected to hypoxia (3h) and reoxygenation (one hour). Imaging
was initiated at the beginning of reoxygenation for changes in ROS levels. GCA
overexpression (AdGCA) exacerbated hypoxia-induced ROS production during
reoxygenation reflected by a significant (p<O.05) increase in DCF fluorescence
(Figure 38A-C), whereas GCA inhibition (PUGNAc) attenuated hypoxia-induced
ROS generation compared to Vehicle (Figure 38A, D-E).

123

D)

8)
+AdNuINO

A)

Reoxygenation Time

61

AdNull +Hypoxia

7o+--......--r--r--..---r----.
1

AdGCA + Hypoxia

"

~

~

~

~

1

~

11

21

31

41

51

61

Tine (minutes)

Tme Imlnutes)

E)

C)

**

Vehicle +Hypoxia

CJAdNull
• AdGCA
PUGNAc +Hypoxia

Nonnoxia

Hypoxia

Figure 39. Evaluation of post-hypoxic ROS production in NRCMs treated with
AdNull , AdGCA, Vehicle or PUGNAc using DCF (n=4 per group). Hypoxia
induced ROS production. Genetic overexpression of GCA exaggerated, while
pharmacologic inhibition of GCA (PUGNAc) mitigated post-hypoxic ROS
production. A) Representative montage showing DCF fluorescence. B)
Quantitative changes in mean DCF fluorescence (expressed as %) in NRCMs
infected with AdNull or AdGCA using time-lapse fluorescent microscopy C. Bar
graph showing the change in DCF fluorescent intensity between 1 and 61
minutes in NRCMs infected with AdNull or AdGCA. D) Quantitative changes in
mean DCF fluorescence (expressed as %) in NRCMs treated with Vehicle or
PUGNAc using time-lapse fluorescent microscopy E) Bar graph showing the
change in DCF fluorescent intensity between 1 and 61 minutes in NRCMs
infected with Vehicle or PUGNAc. *P<O.05 vs. AdNull or Vehicle, **p<O.05 vs.
AdNull + Hypoxia or Vehicle + hypoxia.
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G.2.iii. Effects of O-GlcNAc manipulation on catalase, SOD and GPX
expression: To determine if alteration in the expression of oxidative stress
response enzymes, glutathione peroxidase, superoxide dismutase and catalase
was responsible for the O-GlcNAc mediated decrease in post-hypoxic ROS
generation, real time PCR for Cat, GPX, and SOD mRNA levels was performed
on RNA from normoxic NRCMs treated with AdGFP, AdGCA, Vehicle or
PUGNAc.

OGT overexpression (AdOGT) did not significantly altered (p>O.05)

GPX, SOD, and Cat expression (Figure 39A). Moreover, neither overexpression
of GCA (AdGCA) nor inhibition of GCA (PUGNAc) significantly changed GPX
and SOD expression (Figure 39A & B).
significantly

diminished

while

GCA

GCA overexpression (AdGCA)

(Figure

39A)

inhibition

significantly

augmented Cat expression despite no change in protein levels (Figure 39B).
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Figure 40. Expression of antioxidant enzymes: superoxide dismutase (S001 &
S002). glutathione peroxidase (GPX) and Catalase (Cat), evaluated via real time
PCR in NRCMs treated AdGFP, AdOGT, AdGCA, Vehicle or PUGNAc
(n=4/group). A) Genetic overexpression of OGT did not affect S001, S002,
GPX and Cat expression. Even though S001, S002, and GPX expression were
not significantly affected by overexpression of GCA, Cat expression was
significantly reduced. B) Pharmacological inhibition of GCA activity did not affect
S002 expression but significantly augmented Cat expression.
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G.3. Effects of Q-GlcNAc manipulation on Ca2+-induced mPTP formation
Because a hallmark of mPTP is the massive swelling of the mitochondria,
we assessed sensitivity to calcium-induced mitochondrial swelling following
manipulation of O-GlcNAc levels. To test the potential link between O-GlcNAc
modification and a functional biochemical assessment of mitochondrial function
within the mechanistic context of cell survival, cardiac mitochondria isolated from
TT04-, PUGNAc- and Vehicle-treated adult mouse hearts were subjected to
calcium-induced mitochondrial swelling.

Exposure of isolated mitochondria to

supra-physiological concentrations of Ca 2 + permeabilizes the mitochondrial inner
membrane to small solutes « 1.5 kDa) (108).

Mitochondria isolated from

vehicle- PUGNAc- and TT04-treated mice were intact (Figure 40A), were free of
cellular debris (Figure 40B), and maintained stable, calcium-free absorbance
levels throughout the assay (Figure 40C).

Cardiac mitochondria from TT04-,

PUGNAc or Vehicle-treated mice were challenged with 0.1 mmollL calcium
chloride and the change in absorbance measured at 520 nm every 2 s.

The

mPTP inhibitors, Cyclosporine A and Sanglifehrin A, significantly inhibited
calcium-induced swelling in mitochondria from Vehicle- treated mice (Figure 40C)
showing that the swelling was mPTP dependent. Similar results were observed
with mitochondria from TT04- or PUGNAc-treated mice (data not shown).
Adult cardiac mitochondria from TT04-treated mice were significantly
(178 ± 10% of Vehicle) more sensitive to CaCh induced swelling compared with
Vehicle (Figure 40D). Conversely, cardiac mitochondria isolated from PUGNActreated mice revealed resistance to the induction of mPTP. The rate of swelling
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in Figure 400 was calculated as a simple change in absorbance with respect to
time and normalized to the Vehicle group. Such functional data complement the
biochemical data in Figure 32. These data provide a novel molecular link
between the identity of an O-GlcNAc-modified protein and a potential direct
mechanism of cytoprotection.
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Figure 41. Assessment of sensitivity to mPTP formation according to calciuminduced mitochondrial swelling.
Adult mouse cardiac mitochondria were
subjected to time control or challenged with 100 IJmollL CaCb. Change in
absorbance (at 520 nm) was measured over time every two seconds using a
spectrophotometer. A) Gross transmitted light evaluation of Percoll-purified
cardiac mitochondria from vehicle-, TT04- and PUGNAc-treated hearts
(respectively) demonstrating structures of ==1 IJm in diameter, with no apparent
cellular debris (image size 100x75 IJm). B) Challenge with 0.1 mmol/L calcium
chloride significantly reduced absorbance (520 nm) in the cardiac mitochondria.
An effect significantly inhibited by mPTP inhibitors; CsA or SfA C). Cardiac
mitochondria from TT04-treated mice were significantly more sensitive to
calcium-induced swelling compared with those from Vehicle-treated mice
(n=4/group). 0) Cardiac mitochondria from PUGNAc-treated mice were
significantly less sensitive to calcium-induced swelling compared with those from
Vehicle-treated mice (n=4/group). *p< 0.05 vs. Vehicle.
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G.4. Effects of OGT manipulation on post-hypoxia

~lIJm

recovery

Specifically motivated by the importance of maintaining mitochondrial integrity to
enhance cell survival, we ascertained whether hypoxia-induced loss of
mitochondrial membrane potential was affected by alterations in O-GlcNAc
levels.

Such an avenue is particularly attractive given the early decline in 0-

GlcNAc levels shown above.

G.4.i Effects of OGT manipulation on post-hypoxia

~lIJm

recovery: Because

mitochondria are arbiters of cell fate and the present data support the role of
OGT as a pro-survival enzyme, we assessed the effects of blocking endogenous
OGT activity on post-hypoxic mitochondrial membrane potential. NRCMs were
treated with AdGFP (100 Mal, 48 hour), AdOGT (100 Mal 48 hour), TT04 (OGT
inhibitor; prior to H/R, 1 IJmollL) or equal volume of DMSO, and loaded with the
mitochondrial membrane potential indicator, tetramethylrhodamine methylester
(TMRM; 50 nmoI/L). Cardiac myocytes were then subjected to three hours of
hypoxia and one hour of reoxygenation.

During the reoxygenation period,

myocytes were evaluated for changes in mitochondrial membrane potential using
time-lapse fluorescence microscopy. Dissipation of mitochondrial membrane
potential is reflected by a loss of TMRM fluorescence. For reference purposes,
the normoxic group averaged between 205 and 225 AU. Thus, the mitochondria
are not 'increasing' their fluorescence, more precisely, they are 'recovering'.
AdGFP-infected NRCMs loaded with TMRM maintained mitochondrial
membrane potential under normoxia and showed no significant difference in
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mitochondrial membrane potential over time (Figure 41 B).

Overexpression of

OGT (AdOGT) attenuated the loss of mitochondrial membrane potential
compared to AdGFP as shown by increased TMRM fluorescence and thus
protected myocytes from cell death following hypoxia (Figure 41A, B & D).
Inhibition of OGT (via TT04) exacerbated the loss of mitochondrial membrane
potential compared to H/R alone as shown by a further reduction in TMRM
fluorescence and thus sensitized myocytes to mitochondrial damage (Figure
41A, C-D). Such findings support a role for OGT at the level of the mitochondrial
permeability transition pore.
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Figure 42. Assessment of post-hypoxic mitochondrial membrane potential
recovery in NRCMs following manipulation of OGT. TMRM fluorescence was
used to indicate mitochondrial membrane potential (n=6/group) beginning at
post-hypoxic reoxygenation and continuing through the first hour of
reoxygenation. OGT overexpression improved the recovery of mitochondrial
membrane potential compared to AdGFP while OGT inhibition (via TT04)
repressed the recovery of mitochondrial membrane potential compared to
Vehicle. A) Representative montages of post-hypoxic TMRM fluorescence in
cardiomyocytes. B) Graph showing average TMRM fluorescence for AdGFP and
AdOGT infected myocytes over 60 minutes of reoxygenation as index of recovery
of mitochondrial membrane potential. C) Graph showing average TMRM
fluorescence for Vehicle and TT04 treated myocytes over 60 minutes of
reoxygenation. D) Quantification of the change in relative fluorescent intensity
for AdGFP, AdOGT, Vehicle and TT04 treated myocytes. *P<0.05 vs. AdGFP or
Vehicle
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G.4.ii. Effects of GCA manipulation on post-hypoxia ~lIJm preservation: Loss

of mitochondrial membrane potential (Ll4Jm) commits cells to death pathways (4,
175). Consequently, we examined the effects of GCA knockdown on hypoxiainduced loss of mitochondrial membrane potential using TMRM. We assessed
the effects of altered GCA activity on post-hypoxic mitochondrial membrane
potential. NRCMs were treated with either AdGFP (48 hours, 100 MOl), AdGCA
(48 hours, 100 MOl), Vehicle (overnight), PUGNAc (overnight, 200 jJmollL),
Control siRNA (72 hours, 60 nmollL), or GCA siRNA (72 hours, 60 nmol/L) and
loaded with the mitochondrial membrane potential indicator TMRM (100 nmol/L).
Cardiac myocytes were then subjected to either three hours of normoxia, or,
three hours of hypoxia and one hour of reoxygenation. During the reoxygenation
period, myocytes were evaluated for changes in mitochondrial membrane
potential using time-lapse fluorescence microscopy. Dissipation of mitochondrial
membrane potential is reflected by a loss of TMRM fluorescence. For reference
purposes, the normoxic group averaged between 198 and 215 A.U. Thus, the
mitochondria are not 'increasing' their fluorescence, more precisely, they are
'recovering'. Hypoxia/reoxygenation induced mitochondrial membrane potential
loss. GCA overexpression attenuated the post-hypoxic mitochondrial membrane
potential recovery during reoxygenation, shown by impaired recovery of TMRM
fluorescence (Figure 42A-8 & E). Conversely, inhibition of GCA (via PUGNAc or
GCA siRNA) attenuated the loss of mitochondrial membrane potential compared
to vehicle or Control siRNA, as shown by the significant restoration of TMRM
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fluorescence toward that of the normoxic control, and protected cells from posthypoxic mitochondrial dysfunction (Figure 42A, C-E).
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Figure 43. Assessment of post-hypoxic mitochondrial membrane potential
recovery in NRCMs following manipulation of GCA. TMRM fluorescence was
used to indicate mitochondrial membrane potential (n=6/group). GCA
overexpression attenuated, while GCA inhibition (via PUGNAc or via GCA
siRNA) enhanced mitochondrial membrane potential recovery compared to
AdGFP, Vehicle or control siRNA respectively A) Representative montages of
post-hypoxic TMRM fluorescence in cardiomyocytes. B) Graph showing average
TMRM fluorescence for AdGFP and AdGCA infected myocytes over 60 minutes
of reoxygenation as index of recovery of mitochondrial membrane potential. C)
Graph showing average TMRM fluorescence for Vehicle and PUGNAc treated
myocytes over 60 minutes of reoxygenation. D) Graph showing average TMRM
fluorescence for Control and GCA siRNA transfected myocytes over 60 minutes
of reoxygenation. E) Quantification of the change in relative fluorescent intensity
for AdGFP, AdGCA, Vehicle, PUGNAc, Control siRNA and GCA siRNA treated
myocytes. *P<0.05 vs. AdNull or Vehicle or Control siRNA.
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H. TRANSLATION TO IN VIVO MODEL
H.1. O-GlcNAc levels change following myocardial ischemia-reperfusion:
We used the exogenous enzymatic labeling of O-GlcNAc modified proteins, Click
chemistry technique to assess changes in O-GlcNAc levels in the ischemic (area
at risk, n>/=4/group) and nOh-ischemic zones (n>/=4/group) of mice subjected to
40 minutes of myocardial ischemia (MI) via left anterior descendinf coronary
artery ligation or Sham surgery and reperfused for zero, one, four or twenty four
hours. O-GlcNAc levels decreased after 40 minutes of myocardial ischemia in
the ischemic zone for MI group compared to sham group (Figure 43A and 8).
Upon reperfusion, O-GlcNAc levels were :::::1.6-fold higher than sham after 1hr,
and dropped to baseline after 4hrs and 24 hrs of reperfusion (Figure 43A and 8).
Despite changes in O-GlcNAc levels in the ischemic zone of hearts of the MI
group, there was no significant change in O-GlcNAc levels in the non-ischemic
zone from both the MI and Sham groups following ischemia and during the
different durations of reperfusion i.e. zero, one, four or twenty four hours(Figure
43C).

Moreover, myocardial ischemia induced cellular injury which was

exacerbated by reperfusion compared to Sham surgery as reflected in cardiac
troponin I release (cTnl, Figure 430). There was no significant difference in cTnl
release in the Sham group at the different time points (Figure 430).
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Figure 44. Effects of ischemia-reperfusion injury on O-GlcNAc levels. Adult C57
(n=4-6 per group) mice were subjected to 40 minutes of ischemia and reperfused
for 0-24 hours. Evans blue dye was used to delineate ischemic zone (IZ) from
non-ischemic (nIZ) zone. O-GlcNAc levels were assessed via click chemistry for
the non-ischemic and ischemic zones while ischemia-reperfusion injury was
assessed via serum cardiac troponin I (cTnl) levels. A) Representative TAMRAGlcNAc gels for ischemic zone for time points with significant changes in 0GlcNAc levels. Ischemia induced significant decrement, while reperfusion for one
hour augmented O-GlcNAc levels. B) Densitometric quantification of TAMRAGlcNAc gels expressed as percent of sham for ischemic zones show significant
reduction in O-GlcNAc levels following ischemia (zero hour of reperfusion),
augmented O-GlcNAc levels by 1 hour of reperfusion and no change in 0GlcNAc levels by four and twenty four hours of reperfusion compared to Sham.
C) There was no significant difference in O-GlcNAc levels in the Non-ischemic
zones of MI hearts compared with sham hearts. D) Ischemia induced troponin I
(cTnl) release. Reperfusion exacerbated ischemia-induced cTnl release. *P<0.05
vs. Sham
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H.2. Reduction of myocardial infarct size by PUGNAc in vivo: Infarct size is a
major determinant of mortality following myocardial infarction (28, 86). Reducing
infarct size is therefore critical for improving survival following MI.

Indeed,

studies have shown that interventions that reduce infarct size reduce injury in MI
(223, 243). Therefore, we ascertained whether augmentation of O-GlcNAc levels
is sufficient to reduce infarct size in vivo. We intraperitoneally injected mice with
50 mg/kg of PUGNAc (O-GlcNAcase inhibitor) or isovolumic Vehicle eighteen
hours before surgery. Several mice (n=3/group) not undergoing surgery were
also euthanized to determine whether the dosing regimen of PUGNAc was
sufficient to increase cardiac O-GlcNAc levels. As shown in Figure 44A, such
treatment significantly augmented myocardial O-GlcNAc levels compared with
Vehicle treatement.

Additional mice (n>/=8/group) were treated similarly and

subjected to 40 minutes of ischemia via left anterior descending coronary artery
ligation and 24 hours of reperfusion. At the end of reperfusion, Evans blue dye
and 2,3,5-triphenyltetrazolium chloride were used to define the area at risk
(ischemic zone) and infarct size, respectively (Figure 448).

There was no

difference in ratio of the area at risk (AAR) to left ventricle (LV) for PUGNActreated mice compared to the Vehicle-treated mice indicating that the occlusion
point was same for both group (Figure 44C).

PUGNAc treatment significantly

reduced infarct size when normalized to the area at risk or left ventricukar area
compared with Vehicle (Figure 44D).
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Figure 45. Mice were treated with 50 mg/kg PUGNAc or saline Vehicle for
eighteen hours. A) To one group (n=3 per group) of PUGNAc or Vehicle-treated
mice, total cellular protein was isolated from the hearts and western blotting for
O-GlcNAc performed to confirm the ability of PUGNAc to augment O-GlcNAc
levels in the hearts. PUGNAc treatment significantly augmented O-GlcNAc
levels in the heart. B) Representative photomicrographs of mouse hearts
treated with Vehicle or PUGNAc, subjected to 40 minutes of left coronary artery
occlusion, 24 hours of reperfusion and infarct staining. The amount of dead
tissue (white) in the representative PUGNAc heart is reduced compared with
Vehicle. C) Summary data of hearts exposed to the myocardial
ischemia/reperfusion protocol. LV indicates left ventricle. Infarct (INF) size with
respect to the area at risk (AAR) was significantly reduced in the PUGNAc (n=8)
group compared with Vehicle (n=12). *P<0.05 vs. Vehicle.
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H.3. Effects of manipulaiton of Q-GlcNAc levels on cardiovascular
hemodynamics: One potential explanation for the cardioprotective effects may
be that PUGNAc favorably affects cardiovascular hemodynamics, thereby
reducing oxygen demand and by extension, infarct size.

Accordingly, we

measured blood pressure in mice treated with Vehicle (n=3) or PUGNAc (n=3)
and found no significant differences in mean arterial blood pressure (Table 5).
Furthermore, we evaluated LV end diastolic diameter, LV end systolic diameter,
LV fractional shortening, and heart rate and found no differences between the
two groups (Table 5). Similarly, PUGNAc did not alter blood glucose levels in the
mice (143 ± 18 mg/dL) compared to Vehicle treatment (147 ± 20 mg/dL). Such
data indicate that there were no gross reductions in myocardial work or
circulating glucose levels that would explain the salubrious effects of PUGNAc
during myocardial ischemia. Collectively, these findings provide a clinicallyrelevant counterpart to our more detailed and mechanistic in vitro studies.

Table 5: Cardiovascular hemodynamiCS data
Index

Vehicle (n=3)

PUGNAc (n=3)

Mean arterial blood Pressure
(mmHg)

80 ± 3

78 ± 2

LV end diastolic diameter
(LVEDD, mm)

3.33 ± 0.03

3.34 ± 0.24

LV end systolic diameter
(LVESD, mm)

2.30 ± 0.06

2.30 ± 0.20

30.1 ± 2.4

31.0 ± 2.6

360 ± 23

421 ± 33

LV fractional shortening (LVFS,

%)
Heart rate (HR, bpm)
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CHAPTER VI
DISCUSSION

The purpose of this study was to determine whether the post-translational
sugar modification, O-GlcNAc, plays a role in the pathogenesis of myocardial
ischemia-reperfusion injury.
First, we determined if O-GlcNAc signaling changes following in vitro
oxidative stress, hypoxia-reoxygenation, or ER stress, and in vivo myocardial
ischemia. Oxidative stress and ER stress transiently augmented O-GlcNAc
signaling, while hypoxia alone and ischemia alone reduced O-GlcNAc signaling.
Characterizing O-GlcNAc profiles following short-term oxidative stress induction
revealed that O-GlcNAc levels increased early and start decreasing 40 minutes
post-oxidative stress. Hypoxia reduced O-GlcNAc levels, while reperfusion
induced time dependent augmentation of O-GlcNAc levels peaking after six
hours of reoxygenation.

Our present characterization of the changes in 0-

GlcNAc signaling following hypoxia-reoxygenation in cardiomyocytes differs from
that described by Champattanachai et a/ (33, 34). These studies revealed that
O-GlcNAc levels rise following four hours of hypoxia and early reoxygenation (33,
34).

Such disparity raises the possibility that changes in O-GlcNAc levels
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following hypoxia might be dependent on the severity of hypoxia (anoxia vs.
hypoxia) and the composition of the hypoxic medium. In the intact myocardium,
we show that myocardial ischemia caused decrement in GlcNAc levels; while
upon reperfusion, O-GlcNAc levels increased after 1 hour and were back at
baseline by four and by 24 hours of reperfusion in the ischemic zone.
Interestingly, O-GlcNAc signaling did not change in the non-ischemic zone of the
mice subjected to myocardial ischemia-reperfusion injury. Such changes in 0GlcNAc levels in vivo support our in vitro hypoxia-reoxygenation findings. The
decrement in O-GlcNAc levels observed following hypoxia/ischemia could be due
to decreased substrate (glucose) availability. Moreover, hypoxic or ischemic
stress could lead to decreased OGT activity and/or augmented GCA activity.
Studies in isolated perfused rat hearts from Chatham's group reveal that
simulated ischemia alone augments UDP-GlcNAc and O-GlcNAc levels early in
the low-flow phase and then decline by the end of low flow and during reflow(83,
191). The changes in O-GlcNAc signaling following oxidative, hypoxic, ER stress
or ischemic stress highlight the role of O-GlcNAc as a stress response in the
heart. Moreover, these data support previous findings by Zachara et al. showing
that O-GlcNAc signaling acts as a stress signal (333).
Next, we determined whether manipulation of O-GlcNAc levels affects
oxidative stress, ER stress, hypoxia and ischemia-mediated cell death.

In

oxidative stress, enhanced O-GlcNAc signaling with PUGNAc (GCA inhibitor)
delayed oxidative stress-induced decrease in O-GlcNAc signaling as well as
attenuated the severity of the oxidative stress-mediated cardiomyocyte death.
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Moreover, during ER stress, augmented O-GlcNAc levels via elevating OGT
levels and O-GlcNAcase inhibition (with PUGNAc), attenuated ER stressmediated cardiomyocyte death even though decrement of O-GlcNAc levels via
elevation of GCA levels did not affect ER stress-mediated cardiomyocyte death.
Additionally, during hypoxia-reoxygenation, elevated O-GlcNAc levels via OGT
overexpression and O-GlcNAcase inhibition (siRNA or pharmacologically with
PUGNAc) favored O-GlcNAc modification and mitigated cardiomyocyte death
following hypoxia. Conversely, reducing global O-GlcNAc modification via OGT
inhibition (using siRNA, cre-Iox, or pharmacologically with TT04 and TT40) and
O-GlcNAcase overexpression reduced O-GlcNAc levels and exacerbated posthypoxic cardiac myocyte death. Therefore, this project provides evidence that
pharmacologic or genetic manipulation of OGT and O-GlcNAcase affects cardiac
myocyte survival following oxidative stress, ER stress, and hypoxia. Moreover,
the present data suggest that OGT is a critical survival protein, while 0GlcNAcase antagonizes cardiac myocyte survival. Such pro-survival effects of
enhanced O-GlcNAc modification are supported by data from Champathanachi
et al. in which adenoviral (Ad) overexpression of OGT reduced post-hypoxic

H2 0 2-induced cardiac myocyte death (34), while short interfering RNA against
OGT sensitized NRCMs to hypoxia-induced apoptosis (34).

On the other hand,

evidence supporting the antagonistic role O-GlcNAcase on cardiomyocyte
survival following lethal stress is seen several studies by Champattanachai et al.
showing that O-GlcNAcase inhibition (with PUGNAc or NButGT) attenuated
cardiac myocyte death following hypoxia and oxidative stress (33, 34, 190).
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Better still, PUGNAc administration early in the reflow phase has been shown to
improve cardiac functional recovery, reduce troponin release and calpainmediated proteolysis of a-fodrin and Ca 2 +/calmodulin-dependent protein kinase II
compared to untreated Controls in isolated perfused hearts(190).

Here, we

show that the cytoprotective effects of enhanced O-GlcNAc signaling seen in
NRCMs and isolated perfused heart, are relevant in an in vivo setting. Enhanced
O-GlcNAc levels reduced infarct size in mice subjected to ischemia-reperfusion
injury.

Thus, enhanced O-GlcNAcylation of proteins seems essential in the

ability of the cardiac myocytes, and hence the intact myocardium to withstand
lethal stressors.

Such collective insights during oxidant stress, ER stress,

hypoxia, and ischemia are reminiscent of original findings by Zachara et al. of
augmented O-GlcNAc signaling during cell stress (333).
Outside the common connections between cellular stress and O-GlcNAc
levels, there is a body of data indicating that flux through the hexosamine
biosynthetic pathway can augment O-GlcNAc levels and exert cytoprotection in
vitro (33, 34, 82, 189-191) and in vivo (322, 337).

In one in vitro study,

hyperglycemia or treatment of cells with glucosamine (to increase HBP flux),
augmented O-GlcNAcylation of proteins and was associated with increased
cellular viability(33).

Because the hyperglycemia-mediated increase in post-

hypoxic O-GlcNAc levels was blocked by azerserine (a GFAT inhibitor), it
seemed that the protective effect required HBP flux and subsequent O-GlcNAc
modification of proteins.

In addition, in vivo augmentation of O-GlcNAc levels

using glucosamine after severe injury such as hemorrhagic shock has been
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shown to improve cardiac function and peripheral organ perfusion in rats. Thus,
the myocardium, like various tissues and cell lines, possesses the ability to
recruit O-GlcNAc signaling system in times of stress.
stress-responsive

system

suggests

an

endogenous

Such a conserved and
self-defense

system

operative in the heart.
To determine how O-GlcNAc confers cardioprotection, we first identified
candidate proteins modified by O-GlcNAc in the heart. Based on the list of 13
proteins identified (table 3), voltage dependent anionic channel (VDAC) was
most interesting because it is an outer mitochondrial membrane protein and a
putative member of the mPTP.

On this premise, we hypothesized that

enhanced O-GlcNAc protein modification may act (at least partially) on the
mitochondria to effect protection. Ca 2 + accumulation in the mitochondrial matrix
and increased ROS generation are prominent features of post-ischemic and
hypoxic injury, and favor mPTP formation.

Hence, it was logical to determine

whether manipulation of O-GlcNAc signaling affect post-hypoxic Ca 2 + overload
and ROS generation.

Genetic (AdOGT) and pharmacologic (O-GlcNAcase

inhibition with PUGNAc) augmentation of O-GlcNAc levels attenuated hypoxiainduced Ca 2 + overload compared to Vehicle. Conversely, diminished O-GlcNAc
levels (AdGCA) exacerbated hypoxia-induced Ca 2+ overload.

These data

supports previous findings by Nagy et al. showing that enhanced O-GlcNAc
signaling via increased HBP flux or inhibition of GCA (PUGNAc) in neonatal
cardiomyocytes, blocked angiotensin II-induced cytosolic Ca 2 + elevation (222).
On the other hand, inhibition of OGT (with alloxan) abrogated the glucosamine
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mediated inhibition of angiotensin II-induced cytosolic Ca 2 + overload(222). How
O-GlcNAc attenuates Ca 2 + overload in acute stress is unknown.

Since the

primary source for the rise in intracellular Ca 2 + during/following ischemia or
hypoxia might be via reverse functioning NCX(143), it is possible that enhanced
O-GlcNAc levels mitigate hypoxia-induced Ca 2 + overload via glycosylation of
NCX.

Another possible mechanism may be enhanced SERCA2a activity and/or

decreased phospholamban binding to SERCA2a. Such hypothesis is supported
by several

studies

from

Dillmann's

group

showing

that

hyperglycemic

cardiomyocytes and hearts from STZ-induced diabetic mice with elevated 0GlcNAc levels exhibited

prolonged Ca 2 + transients.

hyperglycemic myocytes and

In addition, these

diabetic hearts showed diminished SERCA2a

expression and phosphorylated phospholamban (PLB)(48, 135).

Interestingly,

overexpression of GCA (AdGCA) improved Ca 2 + transients and augmented
SERCA2a expression(48, 135), hence raising the possibility that O-GlcNAc
signaling might infere with calcium handling by affecting SERCA2a expression
and/or activity. If this is true, it is likely that O-GlcNAc signaling acts directly via
glyocsylation of SERCA2a or indirectly by modifying an upstream kinase.
Another question is whether manipulation of O-GlcNAc signaling affects
SERCA2a expression and PLB phosphorylation at baseline (non-pathological
conditions) in the heart.

We also show that manipulation of O-GlcNAc signaling

affects mitochondrial Ca 2 + overload.
mitochondrial uniporter.

Ca 2 + likely enters the mitochondria via

Because there exist a mitochondrial OGT isoform

(mOGT)(198) which is thought to be membrane bound(115), it is possible that
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mOGT interacts with mitochondrial Ca 2 + uniporter preventing Ca 2 + uptake into the
mitochondria. Such a hypothesis remains to be tested.
In addition to its roles in signal transduction and in regulation of redox cell
signaling, ROS generation contributes to myocardial ischemia-reperfusion injury
(183). Therefore, we ascertained whether manipulation of O-GlcNAc levels
attenuated post-hypoxic ROS generation. Enhanced O-GlcNAc levels (AdOGT
and

PUGNAc)

blocked

hypoxia-mediated

ROS

generation

while

overexpression (AdGCA) exacerbated hypoxia-induced ROS generation.

GCA
One

might hypothesize that O-GlcNAc signaling attenuates hypoxia-induced ROS
generation by upregulating the expression and/or activity of antioxidant enzymes:
catalase (Cat), glutathione peroxidase (GPX), and superoxide dismutase (SOD).
Transcription of oxidative stress responsive enzymes, catalase and MnSOO
(S002) is regulated by forkhead box 01 (Fox01). Fox01 is a nutrient and stress
sensor known to playa regulatory role in diabetes. Recently, Fox01 was shown
to be O-GlcNAc modified. O-GlcNAc modification of Fox01 activates Fox01 and
can in turn lead to activation of transcription of oxidative stress response
enzymes Cat and MnSOO. Therefore, we evaluated whether manipulation of 0GlcNAc levels alter mRNA expression of catalase, superoxide dismutase or
glutathione peroxidase in normoxia. Neither augmented O-GlcNAc (AdOGT and
PUGNAc) nor diminished (AdGCA) O-GlcNAc levels significantly altered baseline
mRNA levels of superoxide dismutase and glutathione peroxidase.

However,

inhibition of GCA (PUGNAc) augmented, while overexpression of GCA, reduced
baseline catalase mRNA levels despite no change in catalase protein levels.
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Because our hypoxia-reoxygenation studies last less than twenty four hours we
do not believe the reduction in post-hypoxic ROS generation seen with
augmented O-GlcNAc levels involves de novo synthesis of antioxidant enzymes.
Instead, if O-GlcNAc signaling affects antioxidant enzymes SOD and GPX, we
expect it to be at the level of the enzyme activity. The alteration in Cat expression
with GCA manipulation partially explains the exacerbated post-hypoxic ROS
generation with GCA expression and reduced ROS generation with GCA
inhibition.

Another possible hypothesis could be that O-GlcNAc signaling

enhances oxidative phosphorylation. Studies show that augmenting glucose flux
improves ischemic tolerance of the heart, potentially through an elevation in
glycolytic ATP production and reduction of fatty acid oxidation (65, 274). The
present data involve alterations in a glucose-derived metabolic signal, O-GlcNAc,
leading one to question whether its manipulation would affect ATP levels. Such
questions might be justified because of the present data indicating mitochondrial
(including

VDAC)

and

metabolic

(e.g.

glyceraldehyde-3-phosphate

dehydrogenase, fructose-bisphosphate aldolase, pyruvate kinase as an 0GlcNAc target) proteins are O-GlcNAc modified.

If alteration in O-GlcNAc

modification of these enzymes affects their function, then it might be reasonable
to expect changes in cellular ATP levels. Moreover, one of VDAC's physiological
functions is to facilitate ATP transport across the outer mitochondrial membrane.
However, because the HBP normally uses less than 5% cellular glucose, minimal
changes in glycolytic ATP (via fructose-6-phosphate) should occur, assuming 0GlcNAc modification of such enzymes would not affect their activity. We show
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that inhibition of OGT (via TT04) did not affect ATP levels in cardiac myocytes [0
IJM TT04 (26.3 ± 15.3 nmol/Llmg protein) vs. 2.5 IJM TT04 dose (26.3 ± 11.9
nmoI/Llmg)]. In agreement with this notion, Champattanachai et a/. found that
glucosamine treatment in cardiac myocytes did not significantly affect ATP
levels(33}. The effects of altered O-GlcNAc signaling on post-hypoxic cardiac
mitochondrial respiration remain to be tested. Though the present data suggest
that decrement of OGlcNAc levels did not affect cellular ATP levels, Hu et a/.
recently identified components of mitochondrial respiratory chain complex I, III
and IV to be O-GlcNAc modified (137).

Moreover, Hu et a/. showed that

hyperglycemia augmented O-GlcNAcylation of components of mitochondrial
respiratory chain complex I, III and IV, reduced their activity and decreased
cellular ATP content in neonatal cardiomyocytes (137).

Overexpression of GCA

restored the activity of these complexes as well as the cellular ATP content
(137). Therefore, determining whether such findings in chronic stress are similar
in acute myocardial stress is critical.

In addition, addressing whether baseline

manipulation of OGT and GCA alter the activity of mitochondrial ETC complexes
is critical.

Since mitochondrial ROS is generated during electron transport in

complex I and III, and components of complex I and III are known to be 0GlcNAc modified, it is possible that during myocardial ischemia/hypoxia, there is
reduced O-GlcNAcylation of complex I and III components leading to augment
ROS generation. Therefore, elevated O-GlcNAc signaling might diminish postischemic or post-hypoxic ROS generation via enhanced O-GlcNAcylation of
components of complex I and III.
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Mitochondria are key mediators and regulators of cell death in myocardial
ischemia-reperfusion injury. The mPTP in particular appears to be a critical for
the transition from reversible to irreversible myocardial ischemia-reperfusion
injury(62).
elevated

The mPTP is activated by ROS and Ca 2 +, and both of these are
during

myocardial

ischemia

and

reperfusion.

Numerous

cardioprotective pathways work primarily by inhibition of mPTP formation directly
or by preventing the conditions that promote mPTP formation. Consequently, we
tested the hypothesis that O-GlcNAc signaling mitigated hypoxia/ischemia
mediated mPTP formation.

Augmented O-GlcNAc signaling (PUGNAc)

attenuated Ca 2 + -induced mitochondrial swelling while diminished O-GlcNAc
levels sensitized cardiac mitochondria to Ca 2 +-induced swelling.

Because

mitochondrial Ca 2 + overload and ROS production favor mPTP (63, 141), it is
possible that O-GlcNAc signaling might mitigate mPTP formation indirectly by
attenuated Ca 2 + overload and/or ROS generation. Because, VDAC, a putative
component of mPTP is O-GlcNAc modified, we hypothesized that GlcNAcylation
of VDAC would prevent its interaction with other mPTP components and hence
block mPTP formation. One might dispute such a hypothesis based on recent
findings by Baines et al. showing that mitochondria for VDAC null mice undergo
mPTP (11). However, there is no evidence that cardiac mitochondria deficient of
all three VDAC isoforms undergo mPTP.
Several models of mPTP have been proposed by different groups. In the
model proposed by Halestrap's group, CyP-D when activated by augmented
mitochondrial Ca 2 + binds to ANT and undergoes conformational changes to form
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mPTP (57, 58, 318). CsA blocks mPTP formation by inhibiting the peptidyl-prolyl
cis-trans isomerase (PPlase) activity of CyP-D and also preventing the binding of
CyP-D to ANT(58, 93, 105, 106). Based on this model, O-GlcNAc might mitigate
mPTP formation by GlcNAcylation of CyP-D, inhibiting the PPlase activity of
CyP-D and/or inhibition of the binding of CyP-D to ANT. In the model proposed
by Lemaster's group(128), mPTP could be formed by aggregation of misfolded
integral membrane proteins damaged by oxidant and other stressors and is
blocked by CsA. In this model, CyP-D prevented protein aggregation normally by
binding these proteins (as chaperone) but when activated by augmented
mitochondrial Ca 2 +, dissociated from these proteins. Hence, O-GlcNAc signaling
might attenuate mPTP formation by enhanced CyP-D chaperone function.
Whether CyP-D and ANT are O-GlcNAc modified is unknown.
Opening of mPTP is characterized by the loss of

~ljJm,

massive

mitochondrial swelling, rupture of outer mitochondrial membrane, and the release
of intermembrane components such as cytochrome c(62). Dissipation of ~4Jm is
a critical event early in the process of cell death(175), hence, we tested the
hypothesis that manipulation of O-GlcNAc signaling affects post-hypoxic
recovery

~ljJm.

The present data reveals that augmented O-GlcNAc levels

enhanced post-hypoxic
diminished

~ljJm

~ljJm

recovery.

recovery, while reduced O-GlcNAc signaling

Therefore, inhibition of

~ljJm

loss by O-GlcNAc

signaling may be mediated by prevention of Ca 2+ overload or ROS production in
mitochondria, such that PTP never opens.
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In addition to Ca 2 + overload and increased ROS generation, endoplasmic
reticulum (ER) stress has emerged as a potentially critical element of
ischemia/hypoxia -induced injury.

Consequently, we focused on the potential

ability of O-GlcNAc signaling to directly attenuate ER stress-induced cell death
(in the absence of the confounding condition of hypoxia).

Here, we show that

augmented O-GlcNAc levels (via overexpression of OGT or inhibition of 0GlcNAcase) attenuated the activation of maladaptive ER stress response and
mitigated ER stress-induced cardiac myocyte death. On the otherhand,
overexpression of GCA did not alter BfA or TM-mediated activation of
maladaptive ER stress response. A notable finding in the present study is the
augmentation of O-GlcNAc signaling during ER stress.

It will be interesting to

ascertain the cause for augmented O-GlcNAcylation during ER stress.

One

might conjecture that augmented O-GlcNAc levels may be due to elevated OGT
and/or reduced O-GlcNAcase activities.

Regardless of the mechanism, we

hypothesized that such a response was a pro-adaptive but insufficient response
to the induction of ER stress. The induction of O-GlcNAc signaling during ER
stress might be predicted from the significant literature supporting the role of 0GlcNAc as an acute stress or alarm signal (228, 333).

The present

demonstration of O-GlcNAc signaling may reflect a partially pro-adaptive
response during ER stress.

Clearly, augmentation of O-GlcNAc signaling

rescued cardiomyocytes from ER stress-induced cell death. The new question
relates to the mechanism operative during O-GlcNAc signaling-mediated rescue
of cells undergoing the UPR. The data related to OGT overexpression and 0-
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GlcNAcase inhibition (via PUGNAc) are clear in that there is robust attenuation of
ER stress-mediated cell death (with either BfA or TM).

In addition, it also

appears that such maneuvers designed to augment O-GlcNAc signaling might
limit the severity of the induction of ER stress, as indicated by the general
limitation of the markers of ER stress activation. In this regard, augmented 0GlcNAc signaling might function as a regulator of the initiation/propagation of ER
stress and indirectly attenuate cell death.

In addition, enhanced O-GlcNAc

signaling may directly attenuate cell death, which may be independent of ER
stress mitigation.

Conversely, the data from O-GlcNAcase could initially be

viewed as ambiguous.

Overexpression of O-GlcNAcase (AdGCA) did not

exaggerate any of the ER stress indicators. Interestingly, AdGCA exacerbated
ER stress-mediated cell death when BfA, but not TM, was used as the inducer of
ER stress. Although the precise reason for the apparently discrepant response is
not clear, we hypothesize that the dose of TM used in our system produces
somewhat greater induction of ER stress (as evidenced by the larger increase in
the ER stress markers in the TM experiments) and that AdGCA is unable to
exacerbate this response.
The UPR initially attempts to support restoration of ER homoeostasis and
protect cells from stress.

In fact, Vitadello et al. first demonstrated that

overexpression of Grp94 reduces ischemia-induced cardiomyocyte death(305).
Moreover, Thuerauf et al. showed that subjecting cardiac myocytes to hypoxia
activated XBP1 and XBP1 contributed to protecting post-hypoxic cardiomyocytes
(293). However, prolonged ER stress activates cell death. Induction of the pro-
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apoptotic transcription factor CHOP is a hallmark of ER stress-mediated cell
death.

Here, BfA or TM-induced CHOP expression was attenuated by

genetic/pharmacologic elevation of O-GlcNAc levels (via OGT overexpression
and O-GlcNAcase inhibition). The exact mechanism through which O-GlcNAc
signaling blocks CHOP activation is unknown.

It is known that p38 MAPK

phosphorylates CHOP, which increases its activity(284). Accordingly, O-GlcNAc
signaling may block CHOP phosphorylation, independent of absolute reductions
in protein expression, thereby reducing its activity and subsequent cardiomyocyte
death.

Targeting eukaryotic initiation factor-2 (eIF-2) represents another

potential mechanism in the context of ER stress.

Its activity is regulated by

phosphorylation and indirectly by O-GlcNAcylation. A 67kDa polypeptide (p67)
binds to e1F-2 blocking its phosphorylation and subsequently inhibits protein
synthesis(32). It is plausible that enhanced p67 glycosylation (Le. with AdOGT)
binds to and blocks e1F-2 phosphorylation by e1F-2 kinase. Although transient
reduction in protein synthesis may be pro-adaptive during the early stages of ER
stress, prolonged blockade of protein synthesis is not viable.

Therefore, one

might predict that augmenting O-GlcNAc levels promotes p67 glycosylation and
subsequent blockade of e1F-2 phosphorylation, as one potential mechanism in
the present study. Such possibilities remain to be evaluated.
Although the present study focuses on the acute effects of altered 0GlcNAc signaling, other studies interrogated the role of chronic elevation of 0GlcNAc levels and its possible role in diabetes. Several groups have shown that
prolonged elevation of O-GlcNAc levels attenuates insulin signaling(307, 313),
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though this issue is far from reconciled (29). In the heart, several studies have
linked chronic elevation of O-GlcNAc levels to abnormal cardiomyocyte function.
Clark et al. reported that in neonatal cardiomyocytes enhancing O-GlcNAc
signaling with hyperglycemia, glucosamine, or OGT overexpression prolonged
Ca 2+

transient

decays

whereas

diminishing

O-GlcNAc

signaling

via

overexpression of GCA, improved Ca 2 + transients in cells subjected to
hyperglycemia. Moreover, hyperglycemia decreased SERCA mRNA and protein
expression and this was prevented by GCA overexpression(48}.

Subsequently,

Hu et al. showed that hearts from STZ-induced diabetic mice have increased
OGT expression and O-GlcNAc levels, accompanied by cardiomyocytes
dysfunction.
increased

GCA overexpression significantly reduced O-GlcNAc levels,
SERCA expression,

and

improved

function

in

both

isolated

cardiomyocyte and intact hearts compared to diabetic controls(135}.

More

recently, Hu et al. showed that several proteins of the mitochondrial ETC are 0GlcNAc modified (138).
mitochondrial

ETC

Moreover, hyperglycemia augmented glycosylation of

proteins

and

impaired

mitochondrial

function

while

overexpression of O-GlcNAcase reduced glycosylation of ETC proteins and
reversed the hyperglycemia-mediated mitochondrial dysfunction(138}.

Such

efforts support the emerging notion that O-GlcNAc signaling participates in the
pathogenesis of diabetes. Thus, acute and chronic effects of altered O-GlcNAc
levels may have significantly different implications in the heart. One explanation
for these potentially contradictory effects of enhanced O-GlcNAc signaling in the
acute and chronic settings in the heart may be that acute increases in O-GlcNAc
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signaling may be protective while chronic activation of O-GlcNAc signaling may
produce adverse effects.

Moreover, target proteins for O-GlcNAcylation in

response to short-term increase in O-GlcNAc levels may be different from that
due to sustained increases in O-GlcNAc signaling. Another possible explanation
is based on the concept of allostasis. The theory of allostasis suggests that the
initial biological response to an acute stress is the activation of processes that
are protective and improve survival, however, as the allostatic load is increased;
the stress becomes more frequent and/or continuous such that activation of the
same pathways results in the development of pathology.

Therefore, if

augmented O-GlcNAc signaling is an acute survival response, the development
of path physiology in chronic diseases like diabetes may be partially due to
chronic activation of O-GlcNAc signaling.
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CHAPTER VII

SUMMARY OF FINDINGS AND FUTURE DIRECTIONS
Summary of Findings

Prior to this study, very few studies addressed the role of O-GlcNAc in the
heart in general, and more so, no literature was available on its role in acute
myocardial ischemia. The few studies that examined the role of O-GlcNAc in the
heart were focused on its contribution to the development of diabetic
card iomyopathy.
Our study provides evidence that the heart recruits O-GlcNAc signaling
system in times of stress (Figure 45). Oxidative and ER stress induced transient
increases in O-GlcNAc signaling, while hypoxic/ ischemic stress trigger an initial
decrease in O-GlcNAc signaling.

This notion supports recent findings by

several other groups showing that O-GlcNAc is a stress response signal.
Moreover, we show that pharmacologic or genetic enhancement of O-GlcNAc
signaling attenuated stress induced cellular damage while pharmacologic or
genetic decrement exacerbated stress-mediated cell death.

Therefore, acute

increases in O-GlcNAc signaling in the heart promote resistance to stress, while
short-term reduction in O-GlcNAc signaling sensitizes cells to stress-induced
death.
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We identified potential mechanisms through which enhanced O-GlcNAc
confers cardioprotection.

We show that O-GlcNAc mitigates components of

mitochondrial mediated death pathway.

As show in Figures 35 and 36,

augmented O-GlcNAc signaling attenuates Ca 2 + overload, ROS generation and
subsequent mitochondrial permeability transition pore formation and loss of
mitochondrial trans inner membrane potential. Besides mitigating mitochondrial
induced death pathway, we show that O-GlcNAc signaling may confer
cardioprotection via attenuating the activation of maladaptive unfolded protein
response (Figure 45).

Our proposed mechanisms are not the only likely

mechanisms through which

O-GlcNAc cardioprotects

because numerous

proteins are O-GlcNAc modified in the heart.
Finally, we show that in vivo enhancement of O-GlcNAc levels reduce
infarct size after ischemia-reperfusion in mice.

Such data provide strong

evidence that the protective effect seen associated with increasing O-GlcNAc
levels at the cellular level and supported in isolated organ studies by Chatham's
group can be translated to the in vivo environment.
Although one limitation of this project is the use of young, healthy, isolated
cardiomyocytes, such a reductionist approach was necessary to identify the role
of the key enzymes that regulate O-GlcNAc modification, OGT and GCA, per se,
and maintain the ability to elevate and reduce OGT and GCA activity.
In conclusion, complete understanding of the protective role of O-GlcNAc
in the heart may yield viable therapeutic options to combat post-ischemic
myocardial injury.

Moreover, the present study lays the groundwork for
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understanding the role of O-GlcNAc in more complex cardiovascular phenotypes
such as diabetes, hypertension, obesity, and other pathologies that predispose
patients to heart disease.
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Future Directions

Further investigation is necessary to elucidate more fully how O-GlcNAc
signaling confers cardioprotection at the level of the mitochondria and ER.
For mitochondrial-mediated cardioprotective mechanism, future studies
will focus on understanding the potential interaction between O-GlcNAc
signaling, ROS generation, and mitochondria. Moreover, identifying specific
proteins that are involved with O-GlcNAc-mediated reductions in Ca 2 + overload is
critical for the complete understanding of O-GlcNAc mediated cardioprotection.
We will also determine if other components of the mPTP are O-GlcNAc modified.
With respect to cardioprotection at the level of the ER, future studies will
be geared towards identifying proteins involved with UPR that are O-GlcNAc
modified. In addition, we will determine the mechanism through which O-GlcNAc
attenuates ER stress.
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